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Abstract
CRISPR/Cas9 is the gene editing tool of choice in basic research and poised to become one in clinical
context. However, current studies on the topic suffer from a number of shortcomings. Mutagenesis is
often assessed using bulk methods, which means rare events go undetected, unresolved or are discarded
as potential sequencing errors. Many of the genotyping methods rely on short-range PCR, which excludes
larger structural variants. Other methods, such as FISH, do not provide basepair resolution, making
the genotype assessment imprecise. Furthermore, it is not well understood how Cas9 delivery format
influences the dynamics of indel introduction. Finally, many studies of on-target activity were conducted
in cancerous cell lines, which do not accurately model the mutagenesis of normal cells in the therapeutic
context.
In my thesis, I have investigated on-target lesions induced by Cas9 complexed with single gRNAs
and no exogenous template. I have followed the time dynamics of Cas9-induced small indels as a
function of reagent delivery methods, established an assay for quantification of Cas9-induced genomic
lesions that are not small indels ("complex lesions") and used this assay to isolate and genotype complex
lesions, many of which would be missed by standard methods. I found that DNA breaks introduced
by single guide RNAs frequently resolved into deletions extending over many kilobases. Furthermore,
lesions distal to the cut site and cross-over events were identified. Frequent and extensive DNA damage
in mitotically active cells caused by CRISPR/Cas9 editing may have pathogenic consequences.
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CRISPR Clustered Regularly Interspaced Short Palindromic Repeats.
DDR DNA damage repair.
DSB double-stranded break.
dsDNA double-stranded DNA.
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HR homologous recombination.
IDAA Indel Detection by Amplicon Analysis.
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MMEJ microhomology-mediated end-joining.
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SSTR single-strand template repair.
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Chapter 1
Introduction
1.1 Precise and efficient
modification of DNA
The ability to modify DNA in mammalian cells at
a chosen locus precisely and efficiently is highly
desirable. In basic research, it allows to unambigu-
ously establish the genetic causality. If introduc-
tion of a given DNA modification is accompanied
by a change in phenotype, then this modification
was sufficient for that phenotype to occur. Such
modification has to be precise or else this clear
conclusion may be confounded. If the process is
not efficient enough, then the phenotype may be
difficult to detect or not manifest at all. Precision
and efficiency are also paramount in gene therapy.
Inefficient DNA modification may fail to achieve
the desired benefit. Imprecise modification may
have negative consequences, for example exces-
sive cell death, unintended loss of resistance or
carcinogenesis. Since genetic modifications are
mitotically heritable, even mild side-effects can
accumulate over time and have to be avoided.
Many routinely used ways of modifying
DNA are neither very precise, nor efficient. To
make these methods useful in basic research and
biotechnology, efficiency and precision have to
be enforced by secondary means, like single cell
cloning, breeding, positive and negative selection.
Molecular cloning, transgene insertion, homolo-
gous recombination and Cre-Lox recombination
may serve as examples. For the purpose of clarity,
screens based on random mutagenesis will not be
discussed here, although similar considerations
apply.
Molecular cloning is a set of procedures
that allow modification of about 3-350 kb DNA
molecules in vitro. Typically, the DNA of interest
is amplified using PCR or cut out of the donor
DNA molecule using restriction enzymes. The re-
sulting fragment is then ligated into a plasmid, a
circular piece of DNA with the ability to propa-
gate in bacterial hosts. The plasmid is transformed
into bacteria for amplification (Cohen, 2013; Co-
hen et al., 1972). Restriction enzyme cutting, PCR
amplification and ligation steps are usually reason-
ably precise, but they may not be 100% efficient,
leaving behind unligated or uncut plasmids. Bacte-
rial transformation is rarely 100% efficient either.
Furthermore, as the number and size of fragments
increase, the precision drops and incorrectly lig-
ated plasmids are produced.
Without additional interventions, a cloning
procedure will lead to the production of a mix-
ture of correctly and incorrectly modified plas-
mids, with many bacteria harboring no plasmid
at all. However, this outcome is routinely avoided
by simply including a antibiotic resistance gene
in the destination plasmid and removing non-
transformed bacteria using that antibiotic. Effi-
ciency can be further increased by placing a "sui-
cide gene" (e.g. ccdB toxin, Bahassi et al., 1999)
in the fragment to be replaced, which prevents
undigested or religated backbone from being prop-
agated. Finally, individual plasmids isolated by
single cell cloning can be tested for precision by
PCR, analytic restriction digest and sequencing.
Thus, despite inherent inefficiency and impreci-
sion of the method, a pure and correct product can
often be obtained.
While very useful for modifying small DNA
fragments, molecular cloning cannot be directly
applied to genomic DNA (homologous recom-
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bination being an exception, which is described
in more detail below). The main obstacle is the
short binding site of most restriction enzymes
(≤8 bp), which means even an average bacte-
rial genome would be cut tens of times, making
precise genomic modifications impossible. Fur-
thermore, even though plasmid vectors can be
maintained in bacteria and yeast (with proper ori-
gins of replication), they can only be expressed
transiently in mammalian cells. This makes them
impractical in gene therapeutic context, except
when the expression only needs to be transient
(notably, some solutions to this problem are being
developed, e.g. Broll et al., 2010).
Naturally occuring mobile elements ("trans-
posons") and genomically integrating viruses have
been engineered to enable stable insertion of DNA
of interest ("transgene") into the genome. Such
transgene insertion is often efficient enough to
affect the phenotype without need for selection.
It makes possible the study of gene function by
overexpression of wild-type or mutant product,
genetic marking of cells for lineage tracing stud-
ies and therapeutic restoration of gene expression.
Specific organs and even cell types can be mod-
ified at any time during development, given the
availability of specific delivery methods and pro-
moters.
Nevertheless, in most cases genomic integra-
tion is semi-random, which fails the "precision"
criterion. Thus, no locus-specific editing is possi-
ble. Adeno-associated viruses are an exception, as
they integrate at a defined genomic region. How-
ever, they are severely limited by the amount of
exogenous DNA of interest they can carry (their
"cargo capacity", Weitzman et al., 1994). Acti-
vation of oncogenes by viral elements posed a
significant risk in the past, although newer gener-
ations of vectors reduced it by removing promis-
cuous promoter elements and adding insulators
(Aiuti et al., 2013; Hacein-Bey-Abina et al., 2003;
Schröder et al., 2002). Immune response to the
viral capsid and silencing of viral repeat elements
are also a concern (Chira et al., 2015). Finally,
transgene insertion often cannot be used when
the gene of interest needs to be under fine con-
trol from its local chromatin environment or when
the pathogenic mutation is dominant negative (i.e.
when it actively competes with the wild-type prod-
uct).
Despite all these problems, the only three
FDA-approved gene therapies are based on stable
genomic integration of viral constructs. In two of
these therapies, the virus deliveres a receptor (anti-
CD19) to patient’s T cells, which makes them at-
tack B-cell lymphomas. In the third case, virus is
used to directly deliver a missing gene (RPE65)
into the retina, which prevents progressive vision
loss in patients with Leber’s congenital amaurosis.
Many more therapies based on transgene insertion
are under development.
Precise replacement or deletion of genomic
DNA can be achieved by transfecting the cells
with a linear double-stranded DNA (dsDNA) of
interest flanked by long sequences identical ("ho-
mologous", in this context) to the target region
(Smithies et al., 1985). This homologous recom-
bination or "targeting" approach leads to precise,
but inefficient target modification (1 in 105-108
transfected cells). Furthermore, the rate of random
insertion can be about 1000x higher than that of
on-target editing leading to a risk of confound-
ing off-target mutagenesis (Smithies et al., 1985;
Thomas and Capecchi, 1987). Selection for cor-
rect insertion and against off-target mutagenesis
made the process feasible by substantially enrich-
ing for the desired modification (5-80% correctly
targeted cells among selected ones, Mansour et al.,
1988; Yagi et al., 1993). The selection cassettes
introduced into the genome during targeting may
need to be removed in an additional step, e.g. us-
ing PiggyBac transposition, if "scarless" editing is
desired (Lee et al., 2014; Yusa et al., 2011a). Be-
cause of these issues, targeting is only routinely
applied to engineer embryonic stem (ES) cells,
which can be single cell cloned and individually
screened for correct insertion by PCR. Off-target
insertions can be detected by Southern blotting or
copy-number qPCR assays.
Since edited ES cells injected into a blasto-
cyst can contribute to the germline, introduced
mutations can be studied on an organismal level
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(Bradley et al., 1984; Koller et al., 1989; Thomp-
son et al., 1989). Animals obtained this way can
be bred to homozygosity, yielding a congenic line
with defined DNA modifications. While labori-
ous, homologous recombination has been success-
fully employed to study the whole-organism phe-
notypes of many thousands of DNA modifications,
among others through IMPC project (Austin et al.,
2004). However, it is far too inefficient to create
them directly in vivo, which is crucial when study-
ing effects that are specific to a given tissue or
developmental stage (notably, in vivo selection
methods are being developed e.g. Nygaard et al.,
2016).
Superior control over time and place of DNA
modification can be achieved through the Cre-
lox recombination system (or FLP-FRT; Broach,
1982; Golic and Lindquist, 1989; Schaft et al.,
2001; Sternberg and Hamilton, 1981). The pro-
cess uses Cre, a phage enzyme, which can be ex-
pressed in an inducible and tissue specific manner,
to cause exchange of genetic material ("recombi-
nation") between specific DNA sequences called
lox sites. Combining different positioning, orien-
tation and sequence variants of these sites allows
genomic inversion, deletion, translocation as well
as insertion of exogenous DNA. Recombination
is usually very efficient and precise. Some recom-
bination lesions can even be engineered to be re-
versible, for example by using double-invertible
splice acceptor constructs containing both lox and
FRT sites (Andersson-Rolf et al., 2017; Elling
et al., 2017). For all these reasons, Cre-lox sys-
tem continues to contribute substantially to our
understanding of basic biology, among others in
mice models (Skarnes et al., 2011). However, re-
combination leaves behind a genomic scar, which
may be a confounding factor in some experiments.
This also makes it impossible to introduce single-
nucleotide polymorphisms (SNPs) and indels in
coding regions (unless a combined Cre-lox and
PiggyBac strategy is employed, e.g. Lee et al.,
2014). Finally, the lox sites need to be introduced
by homologous recombination, which creates a
substantial bottleneck in the procedure. There-
fore, similarly to homologous recombination, Cre-
lox cannot be directly applied to adult organisms,
which precludes its use as a gene therapeutic tool.
Discovery of precision nucleases (e.g. HO,
I-SceI, Zinc Finger and TAL Effector Nucleases)
enabled targeted modification of genomes with
precision and efficiency far higher than those of-
fered by molecular cloning, transgene insertion,
homologous recombination or Cre-lox recombina-
tion. While not completely replacing these meth-
ods, they complement some of them and open up
new possibilities. In particular, they enable pre-
cise, genomic, on-target mutagenesis and vastly
improve targeted homologous recombination effi-
ciency. Their primary means of action is similar
to restriction enzymes in that they introduce a
double-stranded break (DSB) at their recognition
site. In contrast to restriction enzymes, the binding
site of precision nucleases is long enough (typi-
cally >15 bp), to enable precise genomic cutting
at most loci. Understanding how the cell reacts to
and repairs the nuclease induced DSB is crucial.
The next section details how naturally occurring
DSBs are resolved by cellular repair mechanisms.
1.2 DSB repair
DSBs are biologically important in many context,
for example as a part of a systematic processes
like V(D)J recombination, class switch recombi-
nation (both crucial to adaptive immunity), meio-
sis or transposition of mobile elements. Under
these conditions, DSBs usually result in a well
defined, localized mutagenic outcome. However,
they are highly cytotoxic when induced outside of
this context. Ionizing radiation, redox metabolism,
nucleotide excision repair and replication fork
collapse are some of the events, which cause
pathogenic DSBs. Notably, so do precision nu-
cleases. Mammalian cells have evolved a variety
of ways to process DSBs, ranging from perfect
repair to induction of programmed cell death. Fail-
ure to repair any DSB can prevent replication and
correct assortment of the DNA. This could lead to
activation of oncogenes or inactivation of tumor
suppressors and thus cancer. Furthermore, inacti-
vation of an essential gene would cause cell death.
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1.2.1 Repair pathways
There is currently good genetic and functional evi-
dence for at least four major DSB repair pathways
(Fig. 1.1): non-homologous end-joining (NHEJ),
microhomology-mediated end-joining (MMEJ),
single-strand annealing (SSA) and homologous
recombination (HR). The degree of end resection
is the major mechanistic factor which determines
the repair pathway usage. NHEJ (also known as
classical-NHEJ) mediates direct rejoining of bro-
ken ends with no or little end-processing, resulting
in either perfect repair or small indels <10 bp in
vitro (Chang et al., 2017). MMEJ (also known as
alternative NHEJ) rejoins mildly resected ends,
often using microhomology of 1-16 bp, and is as-
sociated with inserts >10 bp and deletions >10 bp
(Sfeir and Symington, 2015). SSA requires more
extensive homology of >20 bp and always results
in clean deletion between the homologous regions
(Lin and Sternberg, 1984). HR involves long re-
section and strand invasion of the resected end
into a double stranded template (usually the sister
chromatid), which is guided by homology >50 bp,
and results in near-perfect copying of genetic in-
formation (Jasin and Rothstein, 2013).
NHEJ is the default repair mechanism out-
side of replication, when extensive DSB resec-
tion is effectively blocked (Aylon et al., 2004;
Escribano-Díaz et al., 2013; Ira et al., 2004). In
NHEJ, exposed ends of the break are protected
and brought together by Ku protein complex. If
the ends are not cohesive, they can be resected in a
limited fashion (<10 bp) as well as extended with
templated and non-templated nucleotides (Chang
et al., 2016). Cohesive ends are joined together by
a ligase IV complex, even across a 1 bp gap.
MMEJ was originally discovered as the “sal-
vage” pathway active in Ku knock-out cells (Boul-
ton and Jackson, 1996), which requires limited
resection for its activity. It also repairs mitochon-
drial DNA (which lack ligase IV crucial for NHEJ)
and complex DSBs, such as those induced by ion-
izing radiation (Seol et al., 2018; Tadi et al., 2016).
Removal of the protective Ku complex and limited
resection of about 100 nt by the MRN (Mre11-
Rad50-Nbs1) complex enables MMEJ and pre-
vents NHEJ. Non-proofing polymerase Polθ is
central to MMEJ. Its main function is to add nu-
cleotides to the ends of the break in three ways:
non-templated, templated from the other end (in
trans, resulting in duplications) or templated from
the same end (in cis, resulting in inversions). Fur-
thermore, Polθ actively removes the single-strand
binding protein RPA. This enables annealing of
the small homologies between the ends of the
break, whether natural or created by Polθ action
(Kent et al., 2016; Mateos-Gomez et al., 2017). At
this stage, any non-matching terminal nucleotides
(“flaps”) are removed (Sharma et al., 2015), miss-
ing nucleotides are filled-in and the ends are lig-
ated.
If binding of RPA to single-stranded DNA
(ssDNA) prevails over Polθ activity, the cell
may instead proceed with the end resection (by
Blm/Dna2/Exo1 complex), which enables SSA
and HR. SSA is similar to MMEJ, as it involves
annealing of homologies, flap removal, gap fill-
in and ligation. However, homologies are longer
(>20 bp) and no nucleotide addition is involved.
Therefore, this pathway always results in a simple
deletion.
HR is initiated by replacement of RPA by
another ssDNA binding protein, Rad51 (Jensen
et al., 2010; Taylor and Woodcock, 2015).
This process also prevents SSA repair. The
resected, Rad51-coated end invades into the
dsDNA of the unbroken sister chromatid. It
can progress through either synthesis-dependent
strand-annealing (SDSA) or double-strand break
repair (DSBR). In SDSA, the invading strand is
extended by DNA copied from the sister chro-
matid and recaptured by the other side of the break
(Nassif et al., 1994). SDSA always results in non-
crossover (NCO), since both ends of the break
remain on the same chromosome molecule. In
DSBR, a so-called double Holliday junction (dHJ)
is formed by both DSB ends of the break being
captured in a tangled way with the invaded sister
chromatid (Szostak et al., 1983). Depending on
how this structure is resolved, DSBR can result in
either NCO or crossover (CO).
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SDSA appears to be the predominant HR path-
way in mitosis, consistent with its exclusively
non-crossover outcomes (Andersen and Sekelsky,
2010). Similarly, HR is limited to post-replicative
cells, when a sister chromatid is present. With-
out sister chromatid, HR would have to use the
homolog as the template, which would likely re-
sult in loss of heterozygosity (LOH) and thus loss
of genetic information. Notably, even though HR
usually results in perfect repair of the damaged
locus and thus is a preferred pathway when a tem-
plate is present, it is >1000 times more mutagenic
than regular DNA replication due to lower fidelity
of the involved polymerases (Deem et al., 2011;
Hicks et al., 2010).
Break-induced replication (BIR) can serve
as a backup to the other HR pathways, especially
in collapsed replication forks, during telomere ex-
tension and in any other case, where the second
end of the DSB is difficult to capture. The main
feature of BIR is conservative replication of DNA
from the site of the break till the end of the chro-
mosome, primed by the invading ssDNA. BIR
works even in non-replicative cells and requires
Polα and a specialized Polδ polymerases (Sotiriou
et al., 2016). Mechanistically, BIR can be placed
at a similar level as SSA, since it requires RPA-
coated ssDNA, but is inhibited by excessive end
resection. However, BIR can also utilize Rad51,
unlike SSA (Marrero and Symington, 2010; Ruff
et al., 2016).
Rad51-independent single-strand template re-
pair (SSTR) is a pathway that may have evolved to
enable RNA-templated DNA repair. It has recently
gained prominence as the mechanism for ssDNA
templated genome editing (Gallagher and Haber,
2018). SSTR has been postulated to use proteins
from Fanconi Anemia pathway, which is involved
in repair of interstrand crosslinks (Richardson
et al., 2018).
1.2.2 Cell-cycle arrest, apoptosis
and controlled DSB induction
Even in a simple, unicellular organism such as
yeast, a single DSB in a non-essential locus can
trigger cell death (Bennett et al., 1993). In human
cells, one unrepaired DSB can cause G1 arrest and
10-20 DSBs are enough for a G2 arrest (Deckbar
et al., 2007; Huang et al., 1996). Excessive dam-
age can result in activation of apoptotic pathways
in a p53-dependent or independent manner (Black-
ford and Jackson, 2017; Ciccia and Elledge, 2010;
Roos and Kaina, 2006).
Despite their high mutagenic and carcinogenic
potential, DSBs are induced in many physiolog-
ical processes. Separation of entangled daughter
strands during replication, generation of immune
diversity, meiotic recombination and transposition
of mobile elements rely on them. These processes
involve various specialized enzymes (for exam-
ple topoisomerase II, Spo11, RAG1/2, PiggyBac
transposase) that both catalyze the DSB and mod-
ulate the repair outcome. Whereas restriction nu-
cleases leave a free terminal phosphate that can be
easily religated by NHEJ, the mechanisms men-
tioned above often proceed through either a hair-
pin stage (V(D)J recombination and PiggyBac
transposition, Mitra et al., 2008; van Gent et al.,
1996) or a covalent linkage between DNA and the
enzyme (meiotic recombination, Cre-lox recombi-
nation and disengagement of replicated strands by
topoisomerases; Goto and Wang, 1982; Keeney
and Kleckner, 1995). It is likely that these condi-
tions reduce the oncogenic potential of induced le-
sions compared to spontaneous ones. While such
mutations do occur, for example the translocation
between IgH and Myc loci leading to Burkitt’s
lymphoma, they do so rarely (Alt et al., 2013).
1.2.3 Diversity in cellular DNA repair
While some pathway decision points are well-
described (e.g. resection, strand invasion), a gen-
eral, quantitative model for DNA repair is missing.
In particular, differences in how cells utilize dif-
ferent repair pathways lack good explanation. For
example, little is known about neural DSB repair.
Neurons are post-replicative, which means that
they do not suffer from replication-induced DSB
and are at a lower risk of cancerous transformation.
At the same time, they also cannot use sister chro-
matid to repair other spontaneous DSBs. Since
they are largely irreplaceable due to limited adult
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Figure 1.1: Pathways of DSB repair. Modified from Sung and Klein, 2006.
neurogenesis, they might be less likely to undergo
apoptosis due to DNA damage. Collectively, these
properties may explain why large structural vari-
ants are often found in mature neurons (Cai et al.,
2014).
On the other end of the cellular spectrum,
similar structural mutations and aneuploidies are
seen in early embryos from IVF procedures (Voet
et al., 2011). Consistently, mouse ES cells use
less NHEJ and more mutagenic MMEJ and HR
than the more differentiated mouse embryonic fi-
broblasts (MEF). ES cells also exhibit hallmarks
of chronically unrepaired DNA damage, lack G1
checkpoint and only undergo apoptosis in a p53-
independent manner (Ahuja et al., 2016; Aladjem
et al., 1998; Hong and Stambrook, 2004; Tichy
et al., 2010). It is currently not clear why muta-
genic DNA repair seems to be associated with
early embryos and ES cells and why the conse-
quences of these events are rarely seen in adult
organisms at similar frequencies, although a po-
tential mechanisms involving immune and cellular
elimination of affected cells have been proposed
(Bolton et al., 2016; Daughtry et al., 2018; San-
taguida et al., 2017). The cell-specific DNA repair
may be related to balancing the risk of cancer-
ous mutagenesis, need for timely cell division (for
example during development) and broader conse-
quences of cell death.
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1.3 Precision nucleases
Precision nucleases substantially improved our
ability to modify genomes. By generating a single
DSB at their binding site, they can cause local-
ized mutagenesis (mediated by NHEJ and MMEJ)
and stimulate precise modification of the target
using exogenous DNA templates (by HR or SSTR,
(Richardson et al., 2018; Rouet et al., 1994)). If
the nuclease is expressed constitutively, the reac-
tion will only cease when mutagenesis or tem-
plated editing destroys the binding site. Targeted
mutagenesis of exons is particularly useful in gen-
erating knock-out alleles by introduction of out-
of-frame indels. Furthermore, larger deletions, in-
versions and translocation can also be created by
two simultaneously induced DSBs (see subsection
1.3.3).
Some of the early precision nucleases discov-
ered, such as HO, I-SceI and similar "meganucle-
ases" (Plessis et al., 1992; Sugawara and Haber,
2012) could only bind one pre-defined sequence,
which could not be easily modified by protein en-
gineering (although some examples exist: Cheva-
lier et al., 2002; Rosen et al., 2006; Seligman et al.,
2002; Sussman et al., 2004). Their binding site
would therefore often have to be introduced into
the genome by traditional, low-efficiency homolo-
gous recombination approaches.
Programmable precision nucleases solved that
problem by combining FokI nuclease with Zinc
Finger proteins or TAL Effector domains, which
can be engineered to bind specific DNA sequences.
Since FokI introduces only a single stranded DNA
break, two ZFNs (Zinc Finger Nucleases) or TAL-
ENs (TAL Effector Nucleases) need to bind in
close proximity on opposite dsDNA strands to
cause a DSB (Bibikova et al., 2003; Boch et al.,
2009; Moscou and Bogdanove, 2009; Urnov et al.,
2005). The ability to induce localized DSBs has
allowed a more detailed dissection of the mecha-
nisms involved in DSB repair (Mehta and Haber,
2014). Clinical trials using these tools to treat
genetic diseases as well as to improve immune
response to cancer or HIV by modifying T cells
are under way (clinicaltrials.gov: NCT01044654,
NCT02500849). Direct mutagenesis of integrated
HPV virus using TALENs is also explored (clini-
caltrials.gov: NCT03057912). A long, successful
"track-record" of both ZFN and TALENs, and the
unparalleled binding flexibility of new generation
TALENs (which can be programmed to specifi-
cally bind sequences up to 30 bp with no com-
position constraints) make them tools of choice
for many potential clinical applications. However,
the complexity of design, which prevents many
researchers from directly assembling their own
nucleases and which drives up the cost of commer-
cial solutions, have prevented their wide-spread
use in basic science. This gap was largely filled
by the discovery and development of a simpler,
cheaper and more flexible CRISPR/Cas9 system.
1.3.1 CRISPR – biology and applications
Clustered Regularly Interspaced Short Palin-
dromic Repeats (CRISPR) are genomic DNA ar-
rays found in most prokaryotes, which consist
of repeat sequences interspersed with fragments
of viruses "recorded" during viral invasion. To-
gether with various Cas (CRISPR-associated sys-
tem) proteins it acts as a prokaryotic immune sys-
tem. Recorded viral fragments are used to direct
Cas nucleases to an invading virus, causing its
destruction. A fixed DNA sequence called proto-
spacer adjacent motif (PAM), which is recognized
by the nuclease, needs to be present next to the
target site. This prevents the nuclease from digest-
ing the host DNA, since PAM is not found in the
repeat sequences of the genomic CRISPR array.
Different classes of CRISPR system exist, many
of which remain to be investigated (Wright et al.,
2016).
The CRISPR/Cas9 system from Streptococ-
cus pyogenes (SpCas9) was the first to be repro-
grammed by the researchers to cut chosen se-
quences in vitro in plasmids and in human cell
lines (Cong et al., 2013; Gasiunas et al., 2012;
Jinek et al., 2012; Mali et al., 2013). In its natural
form, it consists of the Cas9 nuclease loaded with
two RNAs: a crRNA (CRISPR RNA) processed
from the CRISPR array (which contains the se-
quence complementary to the target site and part
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of the repeat sequence) and a universal trRNA
(trans-activating crRNA), which mediates the in-
teraction between the Cas9 protein and the cr-
RNA. In biotechnological practice, the two RNAs
are fused into a single guide RNA (gRNA) com-
posed of 20 nt sequence complementary to the
target site and a 76 nt scaffold. When introduced
into cells, the gRNA-loaded nuclease finds the
dsDNA target and cleaves both strands. The PAM
requirement for SpCas9 is a simple 3’ NGG se-
quence (Fig. 1.2). Unlike most transcription fac-
tors and many other Cas9 nucleases, SpCas9 can
bind to and open heterochromatic regions, which
broadens its targeting range (Barkal et al., 2016;
Polstein et al., 2015). The modularity, simple tar-
geting rule and wide genomic range have made
SpCas9 the precision nuclease of choice, largely
replacing ZFNs and TALENs in regular labora-
tory use. It is also the only CRISPR system so far
to enter into clinical trials (e.g. clinicaltrials.gov:
NCT03164135, NCT03166878, NCT03044743).
The targeting range of Cas9 is limited by the
PAM requirement. Since Cas9-induced DSB only
improves the efficiency of repair using exoge-
nous DNA within 10 bp radius of the cut site
(Paquet et al., 2016), the strict PAM requirement
severely limits the number of sites that can be
edited. This problem can be circumvented to some
degree by using a CRISPR nuclease with a dif-
ferent PAM requirement, such as Cas12a (former
Cpf1), C2c1 or Cas9 from other species (Yang
et al., 2016b; Zetsche et al., 2015). Engineered
Cas9 and Cas12a variants with altered PAM speci-
ficities are also available (Gao et al., 2017; Hirano
et al., 2016; Kleinstiver et al., 2015). Notably,
Cas9 from Neisseria meningitis can cleave ssDNA
(but not dsDNA) without PAM limitation (Zhang
et al., 2015). In principle, engineering of a Cas
protein to cleave dsDNA without a PAM require-
ment should be feasible. However, such a protein
would only work with synthetic gRNAs, as a ds-
DNA sequence producing the gRNA would be cut.
Furthermore, its off-target activity will increase
due to a shorter binding region.
Notably, various Cas proteins have been engi-
neered to perform functions other than cleavage of
DNA. Cas9 with an inactivating mutation in one
of its two nuclease domains turns into a nickase
that introduces single-stranded, rather than double-
stranded breaks. Nickase coupled to a deaminat-
ing enzyme has been used as an efficient "base
editor" capable of creating single basepair sub-
stitutions (CG to TA, and AT to GC, Gaudelli
et al., 2017; Kim et al., 2017a; Komor et al., 2016).
While normal activity of base editor Cas9 should
suppress base-excision repair (instead proceeding
through mismatch repair) and avoid creation of a
DSB, indels are still observed at a frequency of
0.1-1%. These are likely caused by mutagenic in-
termediates of residually active base-excision pro-
cess, a DSB caused by simultaneous base-excision
and nicking or a DSB caused by a replication
fork encountering a nick (Simonelli et al., 2005).
Other uses of nickase enzymes are described in
section 1.3.2. A “deactivated” Cas9 with both nu-
clease domains inactivated has been coupled to
numerous effector domains to act as a "genomic
delivery service", mediating among others tran-
scriptional activation, inhibition or chromatin re-
modeling (Chavez et al., 2016; Gilbert et al., 2014;
Kearns et al., 2015; Konermann et al., 2014; Liu
et al., 2016; Thakore et al., 2015; Xu et al., 2016).
Figure 1.2: Schematic of Cas9 DNA cleavage mecha-
nism. From Redman et al., 2016.
1.3.2 Cas9 off-target problem
The specificity of precision nucleases is limited by
two factors. First, while many 23 bp Cas9 binding
sites (including a 3 bp PAM) are unique, many
are not due to repetitive nature of the genome. By
definition, a site which is not unique is impossible
to target specifically. SpCas9 gRNAs with a target-
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ing segment longer than 20 nt can mediate binding
and cutting, but do not confer increased specificity,
possibly because they are trimmed down to 20 nt
in vivo (Ran et al., 2013). The binding site of
Cas12a is 24 bp long, which is the longest known
among Cas enzymes and may underlie its higher
specificity (Fonfara et al., 2016; Zetsche et al.,
2015). No Cas enzyme has so far been engineered
to have a longer binding site.
Second reason for limited specificity is that
mismatches between the gRNA and the target
DNA sequence do not always prevent activity.
Such off-target mutagenesis has been detected
in vivo at sequences mismatched at up to six po-
sitions (including the PAM sequence), as well as
those with 1 bp indels (Akcakaya et al., 2018;
Canela et al., 2016; Hsu et al., 2013b; Jiang et al.,
2016; Lensing et al., 2016; Tsai et al., 2017, 2015).
Frequencies of some of these off-target events are
estimated to be around 0.01% and were obtained
by either tagging of DSBs in vivo (e.g. GUIDE-
seq, Tsai et al., 2015) or by selecting broken DNA
upon in vitro Cas9 digestion (e.g. CIRCLE-seq,
Tsai et al., 2017). Currently, indels resulting from
such putative DSB events cannot be confirmed
using direct amplicon sequencing, which has a
resolution limit of around 0.1% due to inherent
sequencing error rate of the Illumina platform.
Systematic genome-wide studies have excluded
the possibility that Cas9 may modify completely
mismatched targets (Akcakaya et al., 2018; Iyer
et al., 2018; Luo et al., 2018b). Notably, while
Cas9 binding to the DNA is necessary for DSB in-
duction, it is not sufficient. Therefore, the range of
"off-target binding" is likely much larger than that
of "off-target mutagenesis" and may potentially
have consequences for nuclease-deactivated Cas9
enzymes engineered for their "genomic delivery"
function. This may explain recent results ques-
tioning the specificity of CRISPR-interference ap-
proaches (Stojic et al., 2018).
A number of solutions to the off-target is-
sue have been proposed. In practice, targets mis-
matched at more than two positions are cleaved
very rarely. Therefore, choosing a target that dif-
fers on at least two positions from any other tar-
get in the genome is usually sufficient to main-
tain functional specificity. That choice can be im-
proved by algorithms (Elevation, CFD, CCTop
and MIT), which score off-targets based on em-
pirical data and the likelihood of undesired mod-
ification of coding regions (Doench et al., 2016;
Hsu et al., 2013b; Listgarten et al., 2018; Stem-
mer et al., 2015). In clinical setting, where the
patient’s genome is not be completely sequenced
and where specificity is of paramount importance,
empirical methods for detection of off-target mu-
tagenesis may greatly improve gRNA selection
prior to treatment. A number of such in vitro and
in vivo methods are available (Tsai and Joung,
2016).
Since a modification at an on-target locus
is usually more likely than at an off-target mis-
matched by a few nucleotides, the specificity of
mutagenesis can be further increased at the cost of
efficiency by reducing the effective concentration
of the nuclease-gRNA complex. Shorter gRNAs
(17-18nt match) as well as longer, 5’ mismatched
ones were reported to reduce the frequency of
off-target mutagenesis, presumably by decreasing
the affinity towards off-targets that are matched at
the 5’ end. These strategies occasionally came at
a cost of creating new off-target sites and lower
efficiency (Cho et al., 2013; Fu et al., 2014). A
related strategy involves choosing gRNAs that are
purposefully mismatched at the intended target
site with the hope that further mismatches with
off-target sites will increase specificity (Chavez
et al., 2018). Furthermore, a number of SpCas9
variants with increased specificity have been engi-
neered (Casini et al., 2018; Chen et al., 2017; Hu
et al., 2018; Kleinstiver et al., 2016; Slaymaker
et al., 2016), although some of them suffer from re-
duced efficiency (Chen et al., 2017). Some loss of
efficiency has been linked to a 5’ mismatch com-
monly introduced to enable expression of gRNAs
from plasmid vectors (Kim et al., 2017b). While
this suggests improved fidelity enzymes enforce
a match with the target at the 5’ end more strin-
gently than wild-type enzymes, more research into
the structural nature of these functional improve-
ments is warranted.
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Another way to reduce off-target mutagenesis
is to use Cas9 nickase (or FokI-coupled deacti-
vated Cas9), which creates single-stranded breaks.
Analogously to ZFNs and TALENs, two nickase
enzymes directed to two targets in close proximity
of each other (10-30 bp) will induce a DSB. Con-
versely, a single off-target nick would normally
be religated with no mutagenic effect (Guilinger
et al., 2014; Mali et al., 2013; Ran et al., 2013).
This strategy increases the specificity by sacri-
ficing efficiency and targeting range, and by in-
creasing the complexity of the system (as three
components are needed). The off-target problem
will likely continue to stimulate the development
of new tools, detection techniques and compu-
tational methods. Notably, the specificity of the
Cas9 is limited by the particular genetic and bio-
chemical makeup of the target cell, which cannot
always be known accurately (Lessard et al., 2017).
1.3.3 Cas9 on-target damage
The DSB induced by Cas9 and its resolution
by DNA damage repair (DDR) mechanisms is
the principal cause of the mutagenesis and tem-
plated editing. However, a Cas9-induced DSB
differs from one caused by ionizing radiation
or free radicals. In particular, a natural DSB is
unlikely to occur simultaneously on all homolo-
gous sequences (homologs and sister chromatids),
while highly active Cas9 may lead to such an
outcome. Ionizing radiation often generates two
single stranded breaks within 10 bp on opposite
strands, which leads to a staggered DSB. Both
staggered and blunt ionizing radiation-induced
DSBs may also contain blocked ends and dam-
aged nucleotides, which makes them difficult to
repair using NHEJ (Mahaney et al., 2009). Con-
versely, DSBs caused by Cas9 are assumed to
be predominantly blunt and clean, which makes
them a good substrate for non-mutagenic NHEJ
(Jinek et al., 2012). Occasionally, Cas9 induces a
DSB with 1 nt 5’ overhang, which has been linked
to frequent occurrence of 1 bp and larger inser-
tions templated from around the cut site (Lemos
et al., 2018). In addition to an endonuclease activ-
ity, the nuclease domain which cleaves the strand
non-complementary to gRNA may also have ex-
onucleotic activity. This has been demonstrated in
vitro, by resolving radioactively labelled dsDNA
cleaved and digested by Cas9 over the course of
about 10 min (Jinek et al., 2012; Stephenson et al.,
2018). However, no in vivo proof has been pre-
sented so far. Finally, Cas9 remains bound to the
DNA after cleavage (Sternberg et al., 2014). This
could modulate the repair outcome by prevent-
ing proper assembly of the DSB repair machinery.
Indeed, when Cas9 is bound to the transcribed
strand of an active gene, its removal by the RNA
polymerase activity mitigates the effect on DNA
repair (Clarke et al., 2018).
Deletions smaller than 20 bp and insertions of
1-2 bp are the primary outcome of Cas9-induced
DSB, when no template is provided. Each gRNA
induces particular size indels at specific frequen-
cies. This is often described as the "indel pro-
file" of a given gRNA. These profiles are inde-
pendent of the broader genomic context and gen-
erally stable across tested cell lines (Chakrabarti
et al., 2018; Koike-Yusa et al., 2014; Tan et al.,
2015; van Overbeek et al., 2016). However, small-
molecule inhibition of NHEJ skews the profile
towards larger indels, which indicates that dif-
ferential expression of DNA repair pathways in
normal or pathological settings may also influence
the outcome of Cas9 cutting (van Overbeek et al.,
2016). Other potential modifiers include the for-
mat of Cas9 delivery, which ranges from transient
transfection of pure Cas9 protein and synthetic
gRNAs, also called ribonucleoprotein (RNP), to
stable lentiviral transduction of constructs express-
ing both. For example, RNP results in more rapid
mutagenesis, because both components are pre-
assembled and active as they enter the cells. Stable
expression is associated with higher off-target rate,
because both Cas9 and gRNA are present in the
cell for a longer time (Kim et al., 2014; Lin et al.,
2014; Liu et al., 2015; Ramakrishna et al., 2014;
Zuris et al., 2015). In the presence of a template,
both mutagenesis and templated editing can occur.
The efficiency of editing is usually lower than that
of mutagenesis, but varies widely between cell
lines and loci. Efforts to increase it by modulating
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DNA repair pathways and by modifying the Cas9
enzyme, gRNA and template itself, are very active
areas of research (e.g. Chu et al., 2015; Maruyama
et al., 2015; Riesenberg and Maricic, 2018).
Small indels are not the only documented out-
comes of precision nuclease mutagenesis. Single
gRNAs were shown to induce deletions of up to
600 bp in mouse zygotes (Shin et al., 2017). Dele-
tions of up to 1.5kb in a haploid cancer cell line
potentially induced by single gRNAs have been
described, but since the guides were directed to
a small part of the genome and provided as a
pool, the possibility of rare double-cutting events
could not be excluded (Gasperini et al., 2017).
Although lesions non-contiguous with the cleav-
age site have been reported in yeast upon I-SceI
nuclease cutting, no similar events were reported
for Cas9 (Roberts et al., 2012; Sinha et al., 2017;
Yang et al., 2008). Studies using paired gRNAs
to induce localized deletions also reported gener-
ation of more complex genotypes, such as inver-
sions, translocations, endogenous and exogenous
DNA insertions and larger-than-expected dele-
tions (Boroviak et al., 2016, 2017; Canver et al.,
2014; Kraft et al., 2015; Parikh et al., 2015; Zuck-
ermann et al., 2015). It is possible that even single
gRNAs may generate such outcomes, for exam-
ple due to DSB-proximal spontaneous damage or
off-target DSB induction that is concomitant with
on-target cutting.
1.4 Outstanding issues
Accurate characterization of genotypic and phe-
notypic consequences of on-target Cas9 mutage-
nesis is crucial to both basic research and thera-
peutic applications. However, current studies on
the topic suffer from a number of shortcomings.
Mutagenesis is often assessed using bulk meth-
ods, which means rare events go undetected, un-
resolved or are discarded as potential sequencing
errors. Many of the genotyping methods rely on
short-range PCR, which excludes larger structural
variants. Other methods, such as FISH, do not
provide basepair resolution, making the genotype
assessment imprecise. Furthermore, it is not well
understood how Cas9 delivery format influences
the dynamics of indel introduction. Finally, many
studies of on-target activity were conducted in can-
cerous cell lines, which do not accurately model
the mutagenesis of normal cells in the therapeutic
context.
In my thesis, I have investigated on-target le-
sions induced by Cas9 complexed with single
gRNAs and no exogenous template. In chapter 3, I
have followed the time dynamics of Cas9-induced
small indels as a function of reagent delivery meth-
ods (published as Kosicki et al., 2017). In chap-
ter 4, I established an assay for quantification of
Cas9-induced genomic lesions that are not small
indels ("complex lesions"). Finally, in chapter 5 I
used this assay to isolate and genotype complex
lesions, many of which would be missed by stan-
dard genotyping methods (most of the content of
the last two chapters was published as Kosicki
et al., 2018).
Chapter 2
Materials and Methods
2.1 Cell lines and cell culture
JM8A3 mouse ES cell line was derived from a
C57BL/6N blastocyst (Pettitt et al., 2009). CB9,
BC2 and BC8 mouse ES cell lines were de-
rived from F1 cross between C57BL/6N and
CAST/EiJ mice (Strogantsev et al., 2015), a gift
from A.F. Smith. JBG7 and CBA9 are Cas9-
expressing single cell clones derived from JM8 or
CB9 cells, respectively. Cas9 was introduced by
stable transduction using a Cas9-2A-Blast lentivi-
ral construct (in pKLV2 backbone, see Vectors
section) at a low titre to ensure single copy integra-
tion (<0.1% transduction rate). Human HEK293
cell line and its subclone expressing Cas9 from
the same lentiviral Cas9-2A-Blast construct were
single-cell cloned and their karyotype was veri-
fied (a gift from E. Metzakopian). hTERT RPE1,
trp53-/- cell line expressing Cas9 was obtained
from Steve Jackson’s group. AB2.2 mCherry/GFP
reporter cells were a gift from Dr. Xiufei Gao and
Prof. Pentao Liu. 293T cells for lentivirus pro-
duction were obtained from Ao Zhou. Virus was
obtained by lipofectamine LTX mediated trans-
fection of 293T cells with ViraPower Lentiviral
Packaging Mix (Thermo Scientific) and the Cas9-
2A-Blast construct, following manufacturers’ in-
structions.
All ES cell lines were cultured in M15 me-
dia (High-Glucose DMEM, with 15% FSC, β-
mercaptoethanol and L-Glutamate, Gibco) on
sublethally irradiated feeder cells. Feeders were
derived from SNL76/6 cell line (expressing
neomycin resistance and LIF cassette, Ramírez-
Solis et al., 1993) by transgenic insertion of a re-
sistance cassette (blasticidin or puromycin). HEK
cells were cultured in M15 and RPE1 cell lines
were cultured in M10 (High-Glucose DMEM with
10% FSC).
2.2 Vectors
Vectors for expression of gRNAs contained a U6
promoter with a „F+E” scaffold (reported to me-
diate higher levels of mutagenesis than the stan-
dard scaffold, Hsu et al., 2013a) and a Puro-2A-
BFP cassette driven by PGK promoter. Constructs
were flanked by PiggyBac repeats (PBCV back-
bone from Mathias Friedrich), lentiviral repeats
(pKLV1 backbone from K.Yusa, Koike-Yusa et al.,
2014) or both PiggyBac and lentiviral repeat el-
ements (pKLV2 backbone from E. Metzakopian,
Metzakopian et al., 2017). Cas9-expression vec-
tors contained a truncated EF1α (EFS) promoter
driving a Cas9-2A-Blast cassette in a pKLV2
backbone. Hyperactive PiggyBac transposase was
driven by CMV promoter (Yusa et al., 2011b).
See vector schematics in Fig. 2.1. Vectors were
amplified in NEB10β E.coli strain (Thermo Sci-
entific) under Ampicillin selection and purified
using Machelerey-Nagel plasmid extraction kits.
gRNAs were cloned into BbsI digested backbones
using DNA Ligation Kit V.1 (Takara). Subcloned
plasmids were Sanger sequenced at Eurofins or
GATC.
2.3 Transfections, flow cytometry and se-
quencing
Transfections took place in 24W plates coated
with gelatin. About 300,000 wild-type mouse
ES cells were "reverse" transfected with 2.5 µl
2.3 Transfections, flow cytometry and sequencing 13
lipofectamine LTX, 0.5 µl plus reagent (Thermo
Scientific), 200 ng hyperactive PiggyBac trans-
posase (Yusa et al., 2011b), 100 ng of the pKLV2-
PiggyBac Cas9-Blast plasmid and 50 ng of the
PBCV-gRNA-Puro plasmid in 50 µl OptiMEM
following manufacturer’s instructions. For Cas9-
expressing mouse ES cells, 50 ng hyperactive
PiggyBac transposase and 150 ng of the Piggy-
Bac gRNA-Puro plasmid were used. A similar
setup was used for lipofection of 20 pmol of hy-
bridized crRNA:trRNA (Sigma) and 20 pmol of
EnGen Cas9 NLS (NEB), except plus reagent was
omitted. Hybridization was performed by warm-
ing up mixed crRNA and trRNA to 95oC and
letting it cool down at room temperature. Neon
Transfection System (Thermo Fisher Scientific;
1600 v / 10 ms / 3 pulses) was used for electro-
poration of 150,000 mouse ES cells in buffer R
with 6 pmol each of crRNA:trRNA, electropora-
tion enhancer (IDT) and Cas9 protein or 9 pmol
each of crRNA:trRNA and Cas9 protein. Cells
were cultured in M15 media supplemented with
LIF to maintain pluripotence (Williams et al.,
1988). Stable integration of Cas9 and gRNA-
expressing constructs was selected for using blas-
ticidin (10 µg/ml) and puromycin (3 µg/ml), re-
spectively. The drugs were added on day 2 and
cells were maintained in selective media for the
duration of the experiment. Cells were split 1:1
or 1:2 on day 5 (depending on confluency) af-
ter 10-30’ incubation with trypsin, 1:4 on day 7
and 1:6 from then on, any time they were nearing
confluency.
For flow cytometric analysis, around 300,000
cells (1/6 of a near-confluent well) were collected
by trypsinization, transfered to a U-bottomed 96W
plate, washed once and stained for 15-60’ in 50
µl buffer with 1 µg/ml FLAER reagent (Cedar-
lane) or 1:200 anti-Cd9-PE antibody (cat 124805,
Biolegend). After staining, cells were washed
three times and analysed using a Cytoflex flow cy-
tometer. All procedures were performed at room
temperature. PBS+0.1% BSA buffer was used
throughout. All centrifugations were performed
for 1 min at 500 G.
FACS sorting was performed on day 14 us-
ing MoFlow XDP (Beckman Coulter) or SH800
(Sony). Cells were plated at a limiting dilution
of 500-2000 cells per 10 cm feeder plate (yield-
ing around 100-400 colonies) in M15 supplied
with Penicilin/Streptomycin and colonies were
picked 7-10 days later in 96W feeder plates. Ge-
nomic DNA was extracted from grown colonies
by overnight digestion at 56oC using a lysis buffer
supplied with 1 µg/ml proteinase K (100 mM
Tris pH 8.5, 5 mM EDTA pH 8.0, 0.2% SDS,
200 mM NaCl) followed by precipitation us-
ing 100% ethanol with 75 mM NaCl and three
washes with 70% ethanol. DNA was resuspended
in 200 µl T0.1E buffer (10 mM Tris-HCl with
0.1 mM EDTA). PCR amplification was per-
formed using LongAMP or Q5 polymerase (NEB)
following manufacturer’s instructions. The prod-
ucts were resolved on an agarose gel (2% for
primer pairs spanning <1.5 kb, 0.8% otherwise)
and stained using ethidium bromide. If multiple
PBaseCMV
puroRLTR LTRPGK 2A BFPU6 gRNA
PBase
pKLV2-Cas9
PBCV-gRNA
pKLV1-gRNA
pKLV2-gRNA puroR PBPBLTR LTRPGK 2A BFPU6gRNA
puroR PBPB PGK 2A BFPU6 gRNA
Cas9 PBPBLTR LTRblastR2AEFS
Figure 2.1: Vector schematics. LTR = Long Terminal Repeats, lentiviral elements; PB = PiggyBac repeats; blastR
and puroR = blasticidin and puromycin resistance cassettes; LTRs, PBs and promoters (EFS, CMV and PGK PolII
promoters and U6 PolIII promoter) are maked with colors.
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products were present, they were individually cut
out of the gel and purified using QIAquick Gel
Extraction Kit (Qiagen). If only one product was
obtained, the PCR reaction was purified using
AMPure XP magnetic beads (1:1 ratio). Products
were Sanger sequenced at Eurofins or GATC.
Similar procedures as for mouse ES cells were
used with RPE1-Cas9 cell line, with following ex-
ceptions. For flow cytometry experiments, cells
were transfected with 50 ng pKLV2-gRNA-Puro
and 200 ng hyperactive PiggyBac transposase and
selected with puromycin (3 µg/ml) from day 2
till the end of the experiment. For FACS, cells
were transfected transiently with 500 ng pKLV1-
gRNA-Puro plasmid and selected with puromycin
on days 1-3. Instead of limiting dilution plating,
RPE1 cells were single cell sorted on day 17 into
a 96W plate with M10 media supplied with Peni-
cilin/Streptomycin. Plating efficiency was around
10-20% on day 17 after sorting.
Bone marrow cells from a homozygous
C57BL/6N CAS9-EGFP knock-in mouse (Platt
et al., 2014) were isolated by flushing tibias
and femurs in Hank’s Balanced Salt Solution
(Life Technologies) supplemented with 2% Fetal
Bovine Serum (FBS) and 10mM HEPES (Sigma).
Lineage negative cells were isolated using Di-
rect Lineage Cell Depletion Kit Mouse (Miltenyl
Biotec). After isolation and before sorting, cells
were cultured in X-Vivo (Lonza) with 2% FBS,
50 ng/ml stem cell factor, 50 ng/ml thrombopoi-
etin, 10 ng/ml IL-6 (Peprotech). Following a 3 h
initial culture, 100’000 cells were electroporated
(1550 v / 20 ms / 1 pulse) in buffer T with
44 pmols of crRNA:trRNA (IDT). On day 4 they
were stained and sorted as described above. Single
cell cloning was performed in Methocult M3434
media (6000 cells per 3 ml, StemCell Technolo-
gies) and colonies were picked 7-10 days later
into 25 µl of direct PCR lysis buffer (Peqlab).
2.4 Comparison of delivery methods in
HEK cells
For the RNP-electroporation condition, 150,000
HEK cells were electroporated (1700 V, 20 ms,
1 pulse) with 10 pmol Cas9 protein and 10 pmol
hybridized crRNA:trRNA. For other methods,
cells were seeded in 24W plates the day before
the transfection so as to achieve 50%–70% con-
fluency. For PiggyBac and transient plasmid con-
ditions, cells were then transfected with 150 ng
gRNA plasmid, 150 ng Cas9 plasmid, and 50 ng
of either hyperactive PiggyBac transposase or car-
rier plasmid (pBluescript II SK+). For the pro-
tein + plasmid (P&P) and protein + plasmid +
carrier (P&P-carrier) conditions, cells were trans-
fected with two separately prepared mixes: (1)
3 pmol Cas9 protein, (2) 150 ng gRNA plasmid
with or without 200 ng carrier plasmid (pBlue-
script II SK+). For RNP-lipofectamine conditions,
cells were transfected with 3 pmol Cas9 protein,
3 pmol hybridized crRNA:trRNA (regular or sta-
bilized). Plus reagent was added at 1 µL per 1 µg
plasmid and Lipofectamine 3000 at double that
volume. Cas9 protein was mixed with 1.5 µL Lipo-
fectamine 3000. Cells were collected at indicated
timepoints using trypsin, assessed for transfection
effciency by flow cytometry and cell pellets were
frozen for genomic DNA extraction.
Profiling of indels using IDAA procedure was
performed according to the published protocol
(Lonowski et al., 2017). In short, genomic DNA
was extracted, a ~350 bp region around the cut
site was amplified and tagged with a fluorescent
dye using TEMPase Hot Start DNA polymerase
(Ampliqon) and the products were resolved using
a sequenator, yielding the indel profile.
2.5 PacBio sequencing and analysis
PCR amplification was performed using Q5
(NEB) or HiFi Hotstart ReadyMix (Kapa
Biosciences). First 25 cycles used genomic
primers with an adapter overhang (forward: GAT-
GTACAGAGTGATATTATTGACACGCCC, re-
verse: CCAGGGGGATCACCATCCGTCGCCC
or forward and reverse: CGACTCGCTACCAAT-
GAAGACAGC). Products were purified using
AMPure XP magnetic beads. One tenth of the
eluate was used in a secondary 6 cycle PCR reac-
tion to add recommended PacBio barcodes. For
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PigA, these corresponded to different gRNAs and
protein expression levels, whereas for Cd9 they
corresponded to single cell clones. Products were
pooled equimolarly, prepared for sequencing by
ligation of "SMRTbell" adapters by the Bespoke
Sequencing Team (Wellcome Sanger Institute)
and sequenced on the RSII instrument.
Analysis of PacBio data was performed us-
ing command line version of SMRT-Link soft-
ware (pbtranscript 1.0.1.TAG-1470). For the
purpose of calculating PigA locus coverage, a
circular consensus sequences (CCS) were de-
rived from multiple read-throughs of the same
DNA molecule using "ccs --minPasses=1 --
minPredictedAccuracy=0.9". Genome coverage
was calculated with "bedtools genomecov –dz"
(v 2.27.1) using CCS and visualized using gg-
plot2.
Individual PigA and Cd9 alleles were re-
constructed using Iso Seq workflow. In short,
CCS were called using "ccs --minPasses=0 --
minPredictedAccuracy=0.8" and classified into
full length non chimeric ("FLNC", with both
primer binding sites detected) and non full length
("NFL") reads using "classify" command. FL
reads were also split by barcode, separating sin-
gle cell clones (Cd9) or split into bins of 1 kb
size using "separate_flnc" command (PigA). Iter-
ative Clustering and Error correction (ICE) was
peformed on each group (clone or size bin) in-
dividually using "cluster --targeted_isoseq" com-
mand. A custom script rebuilding the mapping
index on each iteration of the clustering was used
to fix a programming bug. Resulting "high qual-
ity" alleles (as classified by the clustering script)
were mapped to the reference genome using "bwa
mem" (v 0.7.17-r1188). Downstream analysis was
performed using custom R (v 3.3.2) and bash
scripts. For the PigA locus, reads were clustered
furthered based on mapping and alleles with less
than four FL reads support were filtered out. For
the Cd9 locus, additional filters based on FL to
NFL ratio and within clone abundance were ap-
plied. Remaining Cd9 alleles were visually in-
spected and ambiguities were resolved by Sanger
sequencing. Additional alleles were discovered by
custom PCRs (to detect larger deletions, large in-
sertions and small indels) and Sanger sequenced.
Lesions both smaller than 6 bp and farther than
20 bp from the cut site, as well as lesions in low
complexity regions were removed from Cd9 alle-
les.
2.6 Bioinformatics
Analysis of IDAA experiments was performed
in R using binner package (https://github.com/
plantarum/binner). Efficiency score was calcu-
lated as 1–(wild-type peak intensity/sum of wild-
type and prominent peaks intensities). Spurious
“–1 bp” signal present in wild-type samples was
estimated to be around 10% of wild-type peak.
This intensity was subtracted from “–1 bp” peak
and added to the wild-type peak in all samples.
Prominent peaks were defined using an arbitrary
cutoff on the sum of intensities over many experi-
ments.
Approximately 25 bp long primers with
melting temperature of 60oC were designed us-
ing Primer3 or Primer3-BLAST. Guide RNAs
were designed using Benchling and CRISPRscan
(Moreno-Mateos et al., 2015), each guide be-
ing mismatched on at least two positions to
any predicted off-target site. Flow cytometric
data were processed with FlowJo (v 10.4.1).
Mixed Sanger traces were resolved using
the online tool PolyPeakParser (Hill et al.,
2014). For visualization purposes, alignment
of alleles (whether derived from PacBio or
Sanger sequencing) was performed using BLAT
(v 35, with settings -tileSize=6 -minScore=50 -
minIdentity=90) and converted into BAM for-
mat using a customized script from Tobias
Marschall (https://github.com/ALLBio/allbiotc2/
tree/master/synthetic-benchmark). All visualiza-
tions were made in R using ggplot2 package.
Chapter 3
Dynamics of indel profiles induced by various
Cas9 delivery methods
3.1 Introduction
3.1.1 Cas9 mutagenesis of genes
CRISPR/Cas9 has made site-specific mutagene-
sis highly efficient. Therefore, experimental and
therapeutic edits can be performed on populations
of cells, even without integration of an exogenous
selection cassette. In many cases, good results can
be achieved without extensive optimization, espe-
cially when cells constitutively express Cas9 or
when selection for the desired phenotype is possi-
ble. In such circumstances, optimization may not
be necessary. However, it may become paramount
when phenotypic selection is impossible, when
Cas9 has to be delivered into the cells, when the
phenotypic effect is small or when cell numbers
are limiting (e.g. patient material).
Ideally, the efficiency of a Cas9 experiment
should be measured on the level of phenotype.
However, it may be expensive, time consuming,
the necessary reagents may not be available, the
gene product may not be expressed in the edited
cells or the phenotypic effect may not be de-
tectable within a reasonable timeframe (e.g. if
cells need to be quickly reintroduced into the pa-
tient). In this case, the genotype may be a good
proxy for the phenotype. This is particularly the
case, if the phenotype-genotype relationship has
been established in a pilot experiment.
3.1.2 Genotyping of small indels
in bulk cell populations
Routine genotyping of bulk cell populations
can be performed by methods such as En-
zyme Mismatch Cleavage (EMC), Indel Detec-
tion by Amplicon Analysis (IDAA), Tracking
of Indels by DEcomposition (TIDE) and Next-
Generation Sequencing (NGS) (Brinkman et al.,
2014; Lonowski et al., 2017; Yang et al., 2015;
Yeung et al., 2005). Each of these method requires
short-range PCR amplification of the genomic re-
gion of interest (<600 bp), followed by various
methods of allele separation and detection.
In EMC, colloquially known as the T7 or Sur-
veyor assay, the pool of PCR products is denatured
and rehybridized, resulting in formation of homo-
and heteroduplexes. The latter are selectively di-
gested by a heteroduplex sensitive endonucleases
(e.g. T7EI, CELI or Surveyor) and separated from
wild-type sized homoduplexes by agarose gel elec-
trophoresis. Quantification of band intensities de-
termines a simple efficiency score. In IDAA, flu-
orescently labelled PCR products are resolved at
basepair resolution and quantified using a frag-
ment analyzer machine (similar to those used in
Sanger sequencing). This yields an indel profile,
the frequency of different-sized indels (Fig. 3.1).
In TIDE, PCR products from wild-type and mu-
tagenized cells are Sanger sequenced and the re-
sulting traces are computationally deconvoluted
into an indel profile. Assessment of templated
editing is also possible using a related TIDER pro-
cedure. In the NGS approach, the PCR products
are sequenced using the Illumina platform. Both
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Figure 3.1: IDAA workflow. Cells are mutagenized in a pool, resulting in small deletions or insertions. The region
of interest is amplified using a triprimer PCR reaction. One of the two genomic primers contains an overhang that
allows annealing and amplification by a universal fluorescently labelled third primer. Fluorescent PCR products
are separated at single basepair resolution and quantified using a fragment analysis machine (a capillary DNA
sequencer). PCR product size (top x-axis) can be expressed as the allele size versus wild-type (wt, bottom x-axis)
and the amount of given product/allele corresponds to the intensity of the peak expressed in relative fluorescent
units (RFU, y-axis). Modified from Lonowski et al., 2017.
indel profiles and editing can be investigated us-
ing computational approaches (CRISPR Genome
Analyzer, CRISPResso, CRISP-R).
EMC is the "quick and dirty" method. It takes
less than a day and offers only a crude quantitative
measure of efficiency, as it cannot distinguish be-
tween in-frame and out-of-frame mutations (both
of which can form heteroduplexes that are cleaved
by the endonuclease). Furthermore, endonucle-
ases used in the assay are not sensitive to single
base changes and heterozygosity at the wild-type
locus may produce spurious signal due to forma-
tion of "natural" heteroduplexes in unedited sam-
ples. IDAA and TIDE resolve alleles by size at
single basepair resolution with sensitivity similar
to NGS (~0.1%, assuming the usual read quality
cut-off). This makes them tools of choice for es-
timation of out-of-frame mutations, a proxy for
functional knockout. When investigating many
pools at once, NGS becomes an economically vi-
able option, as many pools can be sequenced in
one run for the same price. As the only method to
produce sequence level data, it can resolve indels
of same size, but different basepair composition.
This property also allows it to reliably quantify
templated editing. However, NGS is considerably
more time-consuming than other methods to exe-
cute and to analyze.
3.1.3 Factors influencing Cas9 mutagenesis
and genotyping
Genotyping gives an estimate of the overall effi-
ciency of generating mutant alleles. This can be
influenced by generic factors, such as transfec-
tion efficiency (proportion of cells receiving the
reagents) and concentration of reagents within the
cell over time. The latter is influenced by transfec-
tion multiplicity, activity of the gRNA and Cas9
promoters, whether expression constructs are sta-
bly integrated or transiently transfected, etc. If
necessary, most of these factors can be optimized
in a given cell system. Furthermore, the efficiency
varies between different gRNAs, independently
of the generic factors. The underlying reason is
likely a combination of high and accurate expres-
sion of a particular gRNA sequence from a PolIII
promoter (if used), the binding and cutting activity
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of Cas9 at a given locus as well as how often the
given locus reverts to wild-type upon repair.
How mutant genotype translates into gene
knock-out will depend on both gene and gRNA-
specific factors. Knock-out of non-coding genes
is usually achieved by introducing a large dele-
tion with paired gRNAs, as such genes are ro-
bust to small indels introduced by single gRNAs.
Conversely, a small out-of-frame mutations in the
first few exons of a protein-coding gene is of-
ten enough to abolish protein expression through
nonsense-mediated decay (NMD) of its RNA tran-
script. However, alternative splicing and transcrip-
tion start sites may lead to production of func-
tional protein despite such mutations. Activity
of many protein domains is also sensitive to in-
frame mutations. Composition of mutant geno-
types (the "indel profile") is specific to each gRNA
(Chakrabarti et al., 2018; Taheri-Ghahfarokhi
et al., 2018; van Overbeek et al., 2016). In con-
sequence, two guides targeting the same protein
domain with the same overall level of DNA mu-
tation may differ substantially in the proportion
of out-of-frame mutations and thus in the level of
protein knock-out.
Little is known about the factors influencing
the indel profile of a specific gRNA. Microho-
mologies around the cut site are speculated to
contribute to it. Transcription has been reported to
increase mutagenic efficiency of Cas9 in a strand-
dependent manner, which implies it may also in-
fluence the indel profile. However, no general
rules have yet been defined. The indel profile is
therefore usually established empirically for each
gRNA.
Knowing how different factors influence the
"indel profile" may help predict the level of phe-
notypic knock-out. I set out to study two such
previously unexplored factors - time of genotyp-
ing and Cas9/gRNA delivery method. If geno-
typing is performed before the indel profile be-
comes stable, the efficiency may be assessed in-
correctly. On the other hand, delaying genotyping
may be inconvenient, especially when cells need
to be reinjected into the model organism or pa-
tient as soon as possible after the procedure. Simi-
larly, if different delivery methods result in similar
outcomes, they could be interchanged at conve-
nience. If not, the differences could be exploited
to achieve higher phenotypic knock-out. Finally,
different Cas9/gRNA delivery methods may have
different dynamics of mutagenesis. It may be ben-
eficial to know whether genotyping time needs to
be adjusted depending on the method.
3.2 Results
The Cas9 protein and guide RNA may be deliv-
ered into cells in a variety of forms (e.g. plas-
mid DNA, mRNA, protein) and using a variety of
methods (e.g. electroporation, lipofection, trans-
duction). Methods used in this study are sum-
marized in Fig. 3.2. I collected cells at multiple
timepoints post-delivery and analyzed the indels
using IDAA. I chose IDAA, because it offers
rapid results and high resolution at a low cost.
I performed the experiment in a commonly used
HEK293 cell line, known to be amenable to many
delivery methods and previously shown to achieve
high Cas9-induced mutagenesis rates. A validated,
highly efficient gRNA against the ST6GALNAC1
gene (Hansen and O’Shea, 2015), which is silent
in HEK cells, was picked in hope of avoiding
knockout-specific proliferative effects. To min-
imize differences between methods I utilized a
plasmid backbone containing both lentiviral and
PiggyBac functional elements (Metzakopian et al.,
2017).
3.2.1 Transfection and integration
dynamics
Methods compared in this study result in either
stable (lentivirus, PiggyBac) or transient (RNP,
transient plasmid, P&P - protein & plasmid) ex-
pression of Cas9 and gRNA. As neither compo-
nent of the RNP was fluorescent, I did not monitor
the transfection efficiency of this method. As the
Cas9 plasmid contains no fluorescent marker, I
monitored the BFP expression from BFP-gRNA
cassette as a proxy for the overall transfection
and integration efficiency (Fig. 3.3a). Cas9 was
not selected for and therefore the percentage of
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Figure 3.2: Cas9 and gRNA delivery methods. The same gRNA and Cas9 plasmids were used for all experiments.
Yellow circle indicates transfection with Lipofectamine 3000. RNP-electro: electroporation of Cas9 protein and
synthetic two-part gRNA (crRNA+trRNA) using Neon Transfection System. RNP-lipo: as RNP-electro, using
lipofectamine. P&P - protein & plasmid: transfection of Cas9 protein and gRNA-encoding plasmid. A version
with addition of carrier plasmid (pBluescript II SK+) was also used (P&P-carrier). PiggyBac: transfection of
plasmids encoding Cas9 and gRNA together with PiggyBac transposase (resulting in stable cellular integration).
transient plasmid: as PiggyBac, with transposase replaced by the carrier plasmid (pBluescript II SK+). lentivirus:
transduction of HEK cells stably expressing Cas9 with gRNA lentivirus. Vector schematics in the bottom part
of the figure, LTR = Long Terminal Repeats, lentiviral elements; PB = PiggyBac repeats; blastR and puroR =
blasticidin and puromycin resistance cassettes; LTRs, PBs and promoters are marked with colors.
BFP positive cells is an overestimation of overall
number of cells containing both Cas9 and gRNA-
expressing constructs.
PiggyBac and transient methods resulted in
the highest transfection efficiencies on day 2
(>70%), followed by P&P-carrier and P&P (55%
and 40%; Fig. 3.3b). As expected, the BFP expres-
sion was all but extinguished in the transient plas-
mid, P&P and P&P-carrier conditions by day 14.
The few remaining BFP positive cells may indi-
cate rare cases of stable integration of the plas-
mids.
In the PiggyBac condition, 20% of the cells
(about 1/4 of all transfected cells on day 2) re-
mained BFP positive on day 14, indicating stable
transposition of the PiggyBac transposon from the
donor DNA into the genome. Short-term selection
using puromycin (days 10–14) for the genomi-
cally integrated gRNA-BFP construct increased
the percentage of positive cells to 44%.
Data from early timepoints in the lentiviral
transductions was not collected, but the percent-
age of BFP positive cells was maintained at ap-
proximately 50% between days 9 and 14 post-
transduction, indicating stable integration. Selec-
tion for the integrated gRNA-BFP pro-virus be-
tween days 5 and 14 increased this proportion
to 87%. As puromycin normally kills all wild-
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(b) Comparison of transfection levels across methods
and timepoints. Solid line indicates the most likely path
between collected timepoints. Dotted line connects day 7,
the time when selection of lentiviral condition was started
(no data available, efficiency inferred) to day 9 for se-
lected and unselected samples.
Figure 3.3: Transfection efficiency over time. HEK cells transfected with Cas9 and gRNA were analyzed by
flow cytometry at various time points. BFP fluorescence comes from gRNA expressing plasmids and thus likely
overestimates the actual percentage of Cas9/gRNA double-positive cells. The exception is lentiviral transduction,
where cells constitutively express Cas9. As RNP has no fluorescent component, the transfection efficiency of this
methods is unknown. sel.: selected for gRNA construct using puromycin.
type HEK cells (data not shown), I speculate that
remaining 13% of cells were resistant, but ex-
pressed no or little BFP. Since BFP follows the
puromycin resistance gene in the expression cas-
sette (Fig. 3.2), it is possible for a knock-out mu-
tation to occur within BFP without affecting the
puromycin resistance (personal communication,
Konstantinos Tzelepis).
3.2.2 Mutagenesis efficiency over time
I studied the dynamics of indel generation using
IDAA. For RNP and P&P methods I only col-
lected samples up to day 3 post-delivery, on the
assumption that Cas9 protein is degraded by that
time. For other methods, I continued collecting
samples until day 14 (examples of IDAA indel pro-
files in Fig. 3.4a). The mutagenesis efficiency was
calculated as a ratio of intensity of the prominent,
non wild-type peaks to all the peaks (Fig. 3.4a). As
the wild-type size peak may represent rare SNPs
or balanced indels in addition to the wild-type
allele, this efficiency may be slightly underesti-
mated.
On day 3 post-delivery, RNP-electroporation
was the most efficient method (91–93%), fol-
lowed by lentivirus (64%), transient plasmid
(56%), RNP-lipofection, PiggyBac (36%–40%)
and P&P/P&P-carrier (12–17%; Fig. 3.4b). The
transfection efficiency broadly correlated with the
mutagenic efficiency, except for P&P and P&P-
carrier, which induced relatively lower levels of in-
dels. For transient plasmid transfection, no smooth
curve fit could be found for experimental data, in-
dicating some timepoints were outliers. However,
selection for stable PiggyBac integrants between
days 10 and 14 using puromycin more than dou-
bled the final percentage of mutagenized alleles
(from 17% to 38%). Similarly, selection for pro-
virus integration from day 5 to day 14 increased
that percentage from 59% to 86%. Despite stable
Cas9 expression and long-term selection for the in-
tegration of the gRNA construct 100% mutagenic
efficiency was not achieved. This may reflect the
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Figure 3.4: Indel frequency and profiles overtime. HEK cells transfected with Cas9 and gRNA were analyzed by
IDAA at various timepoints.
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inherent limitation of the method, such as inabil-
ity to distinguish substitutions and "balanced" in-
dels from wild-type and occasional misclassifica-
tion of the 1 bp insertion as wild-type due to Taq
polymerase action (see Discussion). Furthermore,
some gRNA-expressing cassettes may have been
silenced independent of the puro-BFP cassette
before mutagenesis could occur.
Both RNP-electroporation and RNP-
lipofection show earliest indels formation at 6h
and 9h post-transfection. Most of the methods
reached their maximum efficiency on day 2 and 3.
Interestingly, transient plasmid and PiggyBac ex-
hibited a significant decrease in efficiency after
day 3, while lentivirus plateaued.
To reduce technical variation, I repeated the
experiment on a single day using transient plas-
mid, RNP-lipofection, PiggyBac, P&P and P&P-
carrier methods (data not shown). On day 3 post-
delivery, I analyzed the cells by flow cytometry
and TIDE. All methods using protein Cas9 (RNP,
P&P, P&P-carrier) achieved the same mutagenic
efficiency of around 12%. Despite P&P-carrier
transfection efficiency being slightly higher than
with transient plasmid method (82% vs 76%), the
mutagenic efficiency was much lower (12% vs
27%). These results indicate that Cas9 protein was
equally likely to co-transfect with synthetic gRNA
as with gRNA plasmid and that Cas9 protein was
the limiting factor for mutagenic efficiency in the
experiment.
Both transfection and mutagenic efficiency
were higher in transient plasmid than PiggyBac
condition on day 3, consistent with a similar dif-
ference on day 14 in the experiment presented
in Fig. 3.4b. Therefore, higher transfection effi-
ciency likely explains the higher mutagenic ef-
ficiency observed at day 14. It is unclear why
there was a difference in transfection efficiency
in the first place. It may be that the carrier plas-
mid in transient method increases the plasmid
entry rate compared to the transposase plasmid,
which it replaces, possibly due to its smaller size
and hence higher copy number. Alternatively, the
transposase may have effectively reduced the con-
centration of the gRNA expressed from the trans-
poson, either by direct transcriptional interference
or by exposing the transposon plasmid to degra-
dation.
3.2.3 Indel profiles over time
To investigate whether the allelic composition
stays stable or fluctuates over time and across
methods, I quantified the relative abundances of
IDAA indel peaks. As larger deletion indels (e.g.
22, 13, 11 and 8 bp) may correspond to microho-
mologies that I found around the target site (data
not shown), I wondered if they would appear later
than the smaller ones. This would be consistent
with the observation that NHEJ which usually cre-
ates small indels is a faster repair pathways than
MMEJ (Mladenov and Iliakis, 2011). In lentiviral
condition, which yielded most reliable data, larger
indels appear later in the timecourse (Fig. 3.4c).
This suggests either some large indels take longer
to form or that small indels (such as 1 bp inser-
tion) and substitutions are susceptible to recutting,
yielding larger indels upon mutagenic repair.
3.2.4 Dynamic effect of gRNA stability on in-
del efficiency
It has been proposed that gRNAs protected from
cellular exonucleases by chemical modifications
may increase the overall indel generation (Hendel
et al., 2015). Therefore, I studied the dynamics of
indel generation using IDAA in cells electropo-
rated with Cas9 protein and either regular or stabi-
lized gRNAs. Both gRNAs showed similar, rapid
indel formation by 6h post-electroporation and
demonstrate comparable indel profile and maxi-
mum efficiency at the end of the experiment on
day 3 (Figs. 3.5). However, the stabilized gRNA
reached its maximum efficiency on day 1, faster
than the regular gRNA by about 24h. It is known,
that gRNA loading is a key regulator of Cas9 en-
zyme function (Jiang et al., 2016) and I speculate
that stabilized gRNA may improve its binding
affinity and/or nuclease activity.
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3.2.5 Comparison of IDAA and
TIDE methods
As both IDAA and TIDE generate indel profiles,
I decided to compare the results for selected sam-
ples. While the overall profiles were similar, the
sensitivity of TIDE differed depending on which
primer was used for the Sanger sequencing re-
action (Fig. 3.6). As IDAA does not involve a
sequencing step, it is not susceptible to this prob-
lem.
3.3 Discussion
I have investigated the time dynamics of indel
profile generation by different methods of Cas9
and gRNA delivery. I showed that the mutagen-
esis and the initial transfection efficiency were
roughly correlated, except when low protein Cas9
transfection was the likely limiting factor. Explicit
measurement of the efficiency of Cas9 delivery,
e.g. by using a Cas9-GFP fusion, would help solid-
ify this finding. I have confirmed RNP delivery is
characterized by rapid indel induction and found
an indication that stabilized gRNAs may further
speed up the process, which could potentially be
useful in therapeutic setting.
3.3.1 Causes and consequences
of mutagenesis efficiency fluctuation
Unexpectedly, when using plasmid transfection
methods (but not lentivirus), the proportion of
mutagenized cells did not plateau at the maxi-
mum level (usually around day 3 or 4), but peaked
temporarily around day 3-4 and then decreased.
One explanation for this effect may be that al-
leles, which end up being perfectly repaired by
the slower process of homologous recombination
remain undetectable for a longer time than the
ones repaired mutagenically. Therefore, I observe
a temporary enrichment for mutagenic genotypes.
Discrepancy between lentivirus and plasmid meth-
ods may be explained by higher frequency of
stable lentiviral integration. Most cells that are
transduced continue expressing the gRNA from
an integrated lentiviral cassette and are eventu-
ally mutagenized, leading to a plateau. In contrast,
many cells in transient plasmid and PiggyBac con-
ditions express the gRNA temporarily from the
unintegrated plasmid, lose the construct due to
cell division or plasmid degradation, repair the
break perfectly and remain wild-type.
Another potential explanation is that cells
mutagenized using the plasmid grow slower and
end up being outgrown by wild-type cells. This
could be due to toxicity associated with the DNA
(lentivirus typically infects at low multiplicity, but
many copies are delivered by transfection) or with
the carrier (lipofectamine). One way to clarify
this issue would be to monitor frequency of alle-
les "in repair" by qPCR and to compare growth
rates. Comparing mutagenic efficiency of RNP-
lipofectamine and RNP-electroporation beyond
day 3 would indicate whether lipofectamine itself
causes the effect.
As a consequence of this dynamic, correct
estimation of the phenotypic effect from a snap-
shot genotype becomes difficult. In the "plateau"
model, premature genotyping leads to underes-
timation of the effect, but the window for cor-
rect genotyping after reaching the plateau is large.
In the "peak" model, premature genotyping may
paradoxically better mirror the ultimate pheno-
typic effect, if only by chance. The decrease, at
least in the PiggyBac condition, seems to take a
long time and is quite substantial (from around
35% on day 3 to around 15% on day 14). One
potential solution to this problem is to genotype
at the peak and include the expected decline in
phenotypic calculations.
3.3.2 Delayed large indel formation
The indel profile in lentiviral condition showed
that larger indels form later (Fig. 3.4c). A recent
paper found a similar effect and attributed it to the
slower repair kinetics of MMEJ (Brinkman et al.,
2018). While this is almost certainly the case early
on in the timecourse, completion of MMEJ does
not generally take many days, as observed in here
(biochemical studies suggest t1/2 of 2-20h, Iliakis,
2009; Perrault et al., 2004). Therefore, late forma-
tion of larger indels remains unexplained. Recut-
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Figure 3.5: Comparison of normal and stabilized synthetic gRNAs. HEK cells were electroporated using Neon
transfection system with protein Cas9 and regular or stabilized synthetic gRNAs. Representative panels from
duplicate experiments are shown.
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Figure 3.6: Comparison of IDAA and TIDE. The sample shown in Fig. 3.4a, lentivirus 3D, was indel profiled by
TIDE analysis using both the forward or reverse Sanger sequencing raw data files. The results were compared
to IDAA generated profiles, where a zoom in of the indel peaks is provided as inset for clarity. Recommended
detection threshold (150RFU) is indicated by the horizontal line. Selected indels are indicated with black triangles.
N = 1.
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ting of small indels and substitutions may be the
cause. If large indels continue to accumulate after
two weeks, it would validate this hypothesis. Con-
versely, lack of additional accumulation would
not falsify this hypothesis as recutting and muta-
genic repair of such indels may be slow enough
to reach an equilibrium with production of new
wild-type alleles by DNA replication. Therefore,
investigation of mutagenic dynamic using gRNAs
with single mismatches could provide a more di-
rect answer.
3.3.3 Caveats of indel profiling
Genotyping of the other delivery methods did not
yield data of sufficient quality to perform a time-
course analysis or to compare indel profiles across
methods. Two issues caused this. First, the low ef-
ficiency of some methods, especially at the early
timepoints, made signal detection and quantifica-
tion difficult. Excess material had to be loaded
to detect weak signal from indel alleles, which
led to a strong wild-type signal overwhelming ad-
jacent –1 and +1 peaks. Furthermore, I assumed
co-linearity between peak intensity and abundance
of an allele. However, for low intensity peaks this
assumption is likely incorrect. Additional experi-
ments to establish a standard curve and quantify
the magnitude of the signal saturation could rec-
tify these issues. The second issue was the pres-
ence of a spurious –1 peak. Since it was detected
in all control samples (with an intensity of be-
tween 5-15% of wild-type peak), I assume it has
been created by the use of Taq polymerase, which
adds a single 3’ adenine to all PCR products with
less than 100% efficiency. This precluded accu-
rate quantification of the –1 indel and likely af-
fected quantification of other peaks as well. Usage
of high-fidelity non-Taq polymerase would likely
remedy this issue.
Finally, this study suffers from lack of repli-
cation. Only a single guide was used and experi-
ments were repeated at most twice. More replica-
tion would increase confidence in the presented
results.
Chapter 4
Detection and quantification
of complex lesions
4.1 Introduction
4.1.1 Mutation reporters
Basic research in genetics, genome engineer-
ing and DNA damage repair uses simple assays,
which allow isolation and quantification of cells
with particular mutagenic events. The Ames test
used to measure the mutagenicity of chemicals is
one example (Ames, 1979). In this assay, bacteria
harboring a mutation that makes them histidine
dependent are exposed to potentially mutagenic
compounds, which causes some of them to be-
come histidine independent. The frequency of this
reversion can be used as a measure of the muta-
genicity of the compound. Furthermore, surviving
bacteria can be analysed to establish the exact
genetic cause of the reversion, which can be the
restoration of the original genotype or a compen-
sating mutation elsewhere in the gene (e.g. restora-
tion of the reading frame). Variations on this assay
continue to be used in genetics and toxicology
research.
Guided by a similar, selective principle, the
first systematic investigation of gene targeting
used the endogenous Hprt gene and an exogenous
neomycin resistance cassette (neoR) to isolate tar-
geted cells (Thomas and Capecchi, 1987). Hprt
plays a central role in the purine salvage pathway
and is dispensable for viability of cultured cells
under normal conditions. Hprt-proficient cells can
be isolated by using hypoxanthine-aminopterin-
thymidine (HAT) medium, which kills cells un-
able to salvage the necessary nucleotides. Con-
versely, 6-thioguanine (6-TG) kills Hprt-proficient
cells, which convert it to a toxic product. The re-
searchers transfected cells with an Hrpt-targeting
construct containing a neoR cassette and isolated
correctly targeted cells by selecting for loss of
Hprt expression and gain of neomycin resistance.
Varying the concentration of the reagents, the
transfection conditions and the parameters of the
vectors itself (like the length of homology arms)
allowed optimization of the experimental proto-
col. In addition to basic research on gene target-
ing, Hprt is commonly used as a safe locus for
insertion of transgenes and as cassette for posi-
tive and negative selection (Conway et al., 2014;
van der Lugt et al., 1991). NeoR split into two
parts, which can recombine following I-SceI in-
duced DSB to form a functional unit, has been
used to study using HR activity, isolate intra and
interchromosomal repair events as well as to quan-
tify the relative length of repair tracts (Brenneman
et al., 2002, 2000; Johnson and Jasin, 2000).
Methods outlined above rely on drug resis-
tance and colony formation for isolation and quan-
tification of mutagenic outcomes. This is poten-
tially problematic, if drug selection interferes with
the repair processes, if non-mutagenized cells
need to be analyzed or if cells of interest do not
form colonies. Furthermore, the need for colony
formation limits the throughput of the procedure,
due to time needed for colony outgrowth and low
density at which cells need to be plated in or-
der to recover pure clones. Discovery and devel-
opment of fluorescent proteins eliminated these
problems, allowing a simple flow cytometric effi-
ciency readout and FACS isolation of both posi-
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Figure 4.1: Assay design. Targeting introns allows quantification and isolation of complex lesions – i.e. lesions
that are not small indels. The position of the gRNA is shown as a vertical line intersecting with the gene structure.
Horizontal lines indicate indels and large deletions.
tive and negative cells (or intermediate states, if
present; Julius et al., 1972; Prasher et al., 1992;
Shimomura et al., 1962). Assays combining I-SceI
induced DSB and fluorescent protein readout con-
tributed substantially to research on DDR, allow-
ing study of genetic requirements of HR (Pierce
et al., 1999), translocations (Richardson and Jasin,
2000), SSA (Stark et al., 2004) and MMEJ (Ben-
nardo et al., 2008). A principle similar to that in
the split-neomycin assay was used, with split fluo-
rescent proteins being placed at different loci and
with different amounts of shared homology. Con-
structs combining multiple fluorescent proteins
were designed to simultaneously quantify rela-
tive contributions of HR and NHEJ (Certo et al.,
2011). An assay in which repair of Cas9-induced
DSB using a ssDNA donor converts BFP to GFP,
and mutagenic repair abolishes fluorescence al-
together, was used to define optimal conditions
for ssDNA donor integration (Richardson et al.,
2016).
Most of the described DDR assays were de-
signed to capture a specific type of mutation using
a positive selection paradigm and often ignoring
the negative population. I speculated that an assay
based on negative selection against small indels,
the most common lesion caused by Cas9 mutage-
nesis, will reveal repair outcomes that have been
overlooked so far. Here, I describe the develop-
ment of this assay.
4.2 Results
4.2.1 Assay design
I sought to establish an assay to detect and quan-
tify cells with Cas9-induced lesions that are not
small indels ("complex lesions"). I reasoned such
an assay could be based on targeting intronic sites
close to an exon (within 500 bp). Small intronic
lesions are normally not expected to affect gene
expression. Conversely, any other large intronic
lesion, such as translocation, inversion or large
deletions may affect gene expression (Fig. 4.1).
Mouse ES cells and hTERT immortalized,
p53-deficient human retinoid pigment epithelial
cells (RPE1) were used to establish the assay. In
contrast to cancer-derived cell lines, both cell lines
have a normal karyotype and intact DNA repair
mechanisms, which makes them more representa-
tive of a normal somatic cell. Although mouse ES
cells and embryonic fibroblasts differ in their use
of DNA repair pathways, it is not known how they
compare to other somatic cells (Tichy et al., 2010).
P53 deficiency in the RPE1 cell line enabled easy
characterization, as most Cas9-mutagenized p53-
proficient RPE1 cells undergo apoptosis (Haa-
paniemi et al., 2018). Both ES and RPE1 cell lines
can be single cell cloned, which allows creation
of pure, Cas9 expressing lines as well as clonal
genotypic analysis following mutagenesis.
Following criteria were used to pick targets
for the assay:
• High surface expression or easily detectable
function of the gene, which can be used as
a readout and means of selection.
• Availability of flow cytometric reagents for
detection of gene expression or function.
• "Isolated" exons flanked by more than 2 kb
of intronic sequence in both directions, so
that genotyping can be focused on one exon
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only. Such exons could also be targeted on
both flanks as a control.
• Exons whose complete loss would change
the reading frame of the transcript, so that
no fully functional protein could be pro-
duced without them.
• Exons close to the 5’ end of the transcript,
as frameshifting mutations in these exons
are more likely to trigger NMD.
• Genes which produce a single protein iso-
form (i.e. no alternative splicing and tran-
scription start sites), as multiple ones could
confound the readout.
For the initial study, I considered X-linked
genes, which are present in only one copy in male
mouse ES cells and are functionally hemizygous
in female RPE1 cells, due to X inactivation. This
makes the phenotypic readout stronger and eas-
ier to interpret, since only one copy of the gene
needs to be inactivated to ablate the protein func-
tion. Additionally, in male ES cells I expected
to detect exactly one allele per single cell clone,
which would substantially simplify the genotyp-
ing strategy. Loss of chromosome X is lethal in
male ES cells and they rarely maintain two X
chromosomes. Therefore, detection of a single al-
lele on chromosome X in male cells cannot be
mistaken for detection of two identical alleles or
monosomy, as is the case in female cells or at an
autosomal locus.
I considered Hprt, Lamp2 and PigA as poten-
tial X-linked targets in my assay. Hprt is com-
monly used to enable gene targeting. However,
my previous research indicated that the repeat
rich regions around exons 2 and 3 make geno-
typing and Sanger sequencing particularly prob-
lematic. Furthermore, Hprt mutants can only be
detected by a colony counting assay under 6-TG
selection, which is time consuming. It may also
be unreliable, if cells are plated too densely. Un-
der such conditions some Hprt-deficient cells may
be killed due to high local concentration of toxic
products of 6-TG metabolism created by Hprt-
proficient cells. Lamp2 is a glycoprotein present
at the lysosomal membrane that can also be found
on the surface of mouse ES cells (unpublished
data). However, exons 2-5 of Lamp2 are not com-
pletely isolated, with both intron 2 and 4 being
shorter than 1 kb. Moreover, available data im-
plied Lamp2 may not be expressed highly enough
to allow clear separation between positive and
negative cells. PigA is one of the first elements
of a biochemical pathway, which produces glyco-
sylphosphatidylinositol (GPI) anchors necessary
for attachment of some proteins to the surface of
the cell (Miyata et al., 1993). The activity of the
pathway can be assayed by flow cytometry using
a fluorescent reagent, which binds to N-glycan on
GPI-anchored proteins. This reagent (FLAER) is
a fusion of the FITC molecule (FLuorescin iso-
cyanate) and pro-aerolysin (AER), which is an in-
active form of a bacterial toxin aerolysin (Suther-
land et al., 2007). FLAER is routinely used in clin-
ical practice to diagnose patients suspected to have
paroxysmal nocturnal hemoglobinuria (PNH), a
disease caused by deficient GPI-anchor produc-
tion (Takeda et al., 1993). Genetic inactivation
of PigA by CRISPR/Cas9 leads to complete loss
of FLAER staining. It may result in slower cell
growth, but the effect is modest (Koike-Yusa et al.,
2014). Exon 2 is more than 2 kb away from ex-
ons 1 and 3, and its loss is an frameshifting muta-
tion. Loss of exon 3 is also an out-of-frame muta-
tion, but its proximity to exon 4 (500 bp) makes it
less useful as a target. I chose to develop my assay
based on the PigA gene.
4.2.2 Mouse PigA and human PIGA loci
Cas9 and single gRNA constructs targeting in-
tronic or exonic sites in chromosome X linked
PigA gene were delivered into male JM8 mouse
ES cells by PiggyBac transposition. Stable in-
tegration of both the Cas9 and gRNA express-
ing constructs was selected for using blasticidin
and puromycin, respectively. This system allowed
saturation mutagenesis of targeted loci, because
even perfectly repaired targets would be recut un-
til the site was destroyed. Staining with FLAER
reagent was used to quantify the proportion of
PigA-deficient cells 14 days post-delivery. Initial
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(a) Examples of PigA mutagenesis revealed by FLAER staining, PiggyBac method.
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(c) Frequency of PigA loss, RNP method. Each circle represents one independent cell culture (N = 3).
Figure 4.2: Frequency of PigA loss upon mutagenesis with exonic and intronic guides in mouse ES cells.
Individual guides are identified by numbers (Table 4.2).
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(b) Frequency of PIGA loss. Each circle represents one independent cell
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ones indicate UTRs.
Figure 4.3: Frequency of PIGA loss upon mutagenesis with exonic and intronic guides in human RPE1 cells
using PiggyBac vectors. Individual guides are identified by numbers (Table 4.2).
experiments indicated that cells become FLAER
negative gradually starting at around day 5 and
plateauing at day 10. This is likely because it takes
time for all GPI-anchored proteins to be recycled
from the cell surface. Furthermore, some guides
reached their plateau faster than others, likely due
to guide-specific cutting rate or target-specific
mutagenic repair (compare day 7 and day 14,
Fig. 4.2b).
At 14 days post-transfection, three individual
guides targeting exons 2 to 4 yielded very high
rates of PigA loss (80–97%; Fig. 4.2a and 4.2b,
red dots), consistent with frequent out-of-frame
indels. Guide #37 targeting the 5’ end of exon 2
yielded only 59%, which may be due to creation
of hypomorphic PigA forms with in-frame muta-
tions, as evidenced by intermediate FLAER inten-
sity in some of the transfected cells (Fig. 4.2a).
Notably, guides targeting intronic sites also
yielded PigA-deficient cells at significant frequen-
cies. Ten different guides located 263–520 bp
from the nearest exon caused 8–20% PigA loss,
whereas two guides greater than 2 kb away in-
duced 5–7% loss (Fig. 4.2b, gray and blue dots;
Table 4.2), consistent with the mutagenic effect
being distance-dependent.
I obtained similar results with transient expres-
sion using electroporation or lipofection of ribonu-
cleoprotein complexes (RNP), proving that these
observations were not a consequence of Piggy-
Bac transposition, delivery method, antibiotic se-
lection or cellular response to transfected plas-
mid DNA (Fig. 4.2c). While rates of PigA loss
induced by intronic gRNAs #10 and #15 were
nearly identical to those obtained by PiggyBac
method, exonic gRNAs #48 and #56 were much
less efficient. The difference was likely caused
by slower cutting and mutagenic repair dynam-
ics of the chosen exonic gRNAs combined with
the fact their time of action is limited when using
RNP. Consistently, in PiggyBac experiments the
fraction of PigA-deficient cells plateaued earlier
(on day 7) when using most intronic compared to
exonic gRNAs (Fig. 4.2b).
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To investigate whether loss of PigA expres-
sion upon intronic mutagenesis is an intrinsic
property of undifferentiated mouse ES cells, I re-
peated the experiments in a human female differ-
entiated cell line, RPE1 (Fig. 4.3a). I expected
similar results, since RPE1 is functionally hem-
izygous at the PIGA locus, due to X inactivation.
Complete ablation of FLAER staining was ob-
served only by day 17 in RPE1 cells, later than
in mouse ES cells (data not shown). This may
be due to slower proliferation or increased sta-
bility of GPI-anchored proteins in this cell line.
On day 17, mutagenesis of PIGA with all exonic
and two intronic gRNAs #274 and #276 (<400 bp
away from nearest exon) delivered with PiggyBac
vectors resulted in a loss of PIGA at frequencies
comparable to those observed in mouse ES cells
(86-99% and 8.1-9.4%, respectively; Fig. 4.3b).
An intronic guide #277 (>2 kb away from nearest
exon) and another intronic guide #275 (<400 bp
away) were much less efficient (2.7-3.2%). The
exon-proximal gRNA #275 might have been ex-
ceptionally inefficient at inducing on-target dam-
age.
4.2.3 Autosomal Cd9 locus
Given that only one copy of PigA is present in the
male mouse ES cells I wished to exclude the possi-
bility that the observations reflect some peculiarity
of the lack of a homolog. I considered a number of
autosomal genes, which are highly expressed on
the surface of mouse ES cells (unpublished data)
and whose exonic structure conforms to the con-
ditions outlined above. To be able to distinguish
the homologous chromosomes at the genotyping
stage, I performed the experiments in mouse ES
cells derived from an F1 cross between Mus mus-
culus (BL6) and Mus musculus castaneus (CAST)
mouse strains. Therefore, I was also looking for
genes with high degree of divergence between the
two mouse strains.
Genes fulfilling these criteria included Cd9,
Cd81, Itga6 and Tfrc. Initial flow cytometric tests
confirmed high expression, but revealed sensitiv-
ity of Cd9 and Tfrc to differentiating conditions
(plating on gelatin without LIF supplementation
or dense plating on feeders). Furthermore, Cd81
and to some degree Tfrc proteins were sensitive
to trypsinization, when compared to a milder Ac-
cutase treatment. Exonic guides abolished Itga6
and Cd9 expression, while Cd81 retained subpop-
ulations with unaffected and intermediate expres-
sion. No viability phenotype was observed with
these knock-outs, consistent with previous reports
(Georges-Labouesse et al., 1996; Le Naour and
Boucheix, 2000). Mutagenesis of Tfrc led to mas-
sive cell death, indicating it is an essential gene
for cellular viability of mouse ES cells. This is
consistent with evidence of depletion in knock-
out CRISPR screens and essential role in mouse
development (Blomen et al., 2015; Levy et al.,
1999; Wang et al., 2015). I selected Cd9 instead
of Itga6 for the assay, because of its higher ex-
pression and because I interpreted intermediate
levels of staining with some guides as evidence
that hemizygous populations can be isolated. This
has proven to be misleading (see Discussion), but
has not substantially influenced the results.
Most exonic guides against Cd9 delivered
with a PiggyBac vector yielded over 80% pro-
tein loss. Intronic guides 140-1900 bp away from
the nearest exon generated 2.1-7.1% Cd9 loss
(Fig. 4.4b; Table 4.2). Taking into account a 1.6%
background of Cd9-deficient cells in the untrans-
fected condition, I estimate the true proportion
of Cd9 loss due to intronic cutting to be between
0.5–5.5%. This is consistent with results at the
PigA locus, assuming both Cd9 alleles have to be
destroyed to prevent Cd9 expression. I confirmed
that these results were not an artifact of a spe-
cific mouse ES cell line by using guides against
Cd9 locus in multiple independently derived lines
(Fig. 4.5). Notably, different guides induced differ-
ent levels of Cd9 loss (Fig. 4.4c and Discussion).
To understand the phenotypic outcomes of
Cd9 editing, I isolated single-cell clones muta-
genized with different gRNAs and ascertained
their expression status by flow cytometry. Most
clones retained the Cd9 expression status for
which they were sorted. A few clones exhibited
bimodal expression pattern (at 9-45% frequency),
which may be the result of a mixed clone or
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(a) Examples of Cd9 mutagenesis. A different gate was used for gRNA #80 (see Discussion).
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Figure 4.4: Frequency of Cd9 loss upon mutagenesis with exonic and intronic guides in mouse ES cells using
PiggyBac vectors. Individual guides are identified by numbers (Table 4.2).
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Figure 4.5: Mutagenesis in independently derived mouse ES cells lines. Name of the line indicated on top.
Individual guides are identified by numbers (Table 4.2). Results shown are representative of three biological
replicates. A different gate was used for gRNA #80.
mis-segregation of mutagenized chromatids dur-
ing clone outgrowth (i.e. Cd9-deficient and Cd9-
proficient chromatids segregating into separate
cells). Notably, some of the clones derived from
the Cd9-deficient population induced by intronic
guides were later found to retain, on average,
around 50% of wild-type levels of expression
(Fig. 4.4d). They likely represent a distinct popu-
lation found at the high end of the Cd9-deficient
sorting gate (see Discussion). No cells mutage-
nized with the exonic gRNA #35 and sorted for
"medium" expression of Cd9 retained that status,
ending up as either "loss" or "wild-type" clones.
This confirms that "medium" status is a unique
population induced only by specific gRNAs (e.g.
#80; data not shown).
4.3 Discussion
I have set up a simple flow cytometric assay for
detection and quantification of complex Cas9-
induced genomic lesions. It detected substantial
levels of mutagenesis when targeting intronic sites
at a hemizygous PigA and PIGA loci and an auto-
somal Cd9 locus. This could be caused by either
lesions destroying the nearby exon or ubiquitous
presence of strong intronic regulatory elements at
all intronic loci tested. The latter seems unlikely,
as enhancers are neither ubiquitous, nor do they
often have strong phenotypic effects. I investigate
these hypotheses by directly genotyping PigA and
Cd9-deficient cells in chapter 5.
PigA, PIGA and Cd9 were actively tran-
scribed. Outcomes could be different at inactive
loci, if transcription or chromatin structure in-
terferes with Cas9 activity or DNA repair. Low
chromatin accessibility has been shown to impede
Cas9 binding and lower editing efficiency (Horl-
beck et al., 2016; Uusi-Mäkelä et al., 2018). Since
in my assay both Cas9 and gRNA are constitu-
tively active and since SpCas9 can functionally
open the chromatin (Barkal et al., 2016; Polstein
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Table 4.1: Non wild-type Cd9 expression levels.
Level gRNAs Putative cause
loss all exonic out-of-frame mutation and NMD
low single and paired intronic alternative splicing due to exon skipping
medium exonic #80 and #53 in-frame mutation of exon 3
l-wt all intronic monoallelic mutation
l-wt: low turned wild-type. #53 is a Cpf1 guide targeting exon 3 (data not shown).
et al., 2015), its structure at inactive loci should
not make much difference. When Cas9 is bound to
the non-transcribed strand, it blocks DNA damage
repair proteins from accessing the break and pre-
vents formation of indels at 48 hours post-delivery
(Clarke et al., 2018). It is not clear how the dam-
age in those cells is eventually resolved. There
does not seem to be any clear difference between
intronic gRNAs targeting the template strand and
non-template strand in term of frequency of PigA
loss, but the dataset is not well balanced with re-
spect to strandedness (Table 4.2). A direct experi-
ment at a non-transcribed or temporarily silenced
locus may be the only way to resolve this issue.
Lesions at the PigA locus resulted in either
complete ablation of PigA expression or left the
PigA expression unaffected (except those induced
by gRNA #37, as Discussed in results section).
In contrast, mutagenesis of Cd9 locus had three
distinct, non wild-type phenotypic outcomes sep-
arated by at least an order of magnitude fluores-
cent intensity, termed "loss", "low" and "medium"
in Fig. 4.4c and Table 4.1. This variation in ex-
pression level suggests different underlying geno-
types. A "negative" population was induced by
three different gRNAs against exons 2 and 3 and
may have resulted from out-of-frame indels trig-
gering NMD and complete loss of protein expres-
sion. "Low" was only seen with single intronic
gRNAs and deletions induced by a pair of intronic
gRNAs flanking an exon. It may represent an alter-
native TSS or splice form, which "buffers" against
complete loss of an "out-of-frame" exon 2 or 3.
"Medium" expression was only observed with two
specific gRNAs targeting exon 3 (incl. one Cpf1
gRNA, data not shown), which also induced a
"negative" population. This "medium" state may
result from an in-frame mutations that decreases
the protein affinity for the antibody. This set of
hypotheses can be tested by profiling local indels
and RNA transcripts in cell populations sorted for
their Cd9 expression level. If it is true, targeting
different parts of Cd9 would allow quantification
and isolation of specific classes of genomic le-
sions.
Some cells edited with intronic gRNAs and
sorted for low Cd9 expression were found to ex-
press near wild-type levels of Cd9 after clone
outgrowth. These "low turned wild-type" clones
could stem from the "background" Cd9low popu-
lation observed in the negative control (Fig. 4.4b).
Such population would be partially differentiated
due to prolonged culture on gelatin with LIF sup-
plementation. However, in a control experiment
using gRNA against an irrelevant locus only about
3% of the expected number of such Cd9low cells
formed colonies (all retaining wild-type expres-
sion; data not shown). Therefore, they would not
have contributed substantially to the "low turned
wild-type" population observed here. Observation
that these clones express on average 50% less
Cd9 than "true wild-type" clones indicates that
they may represent a hemizygous population (see
chapter 5) If this is the case, then exonic gRNAs
should also induce a similar population.
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Table 4.2: Flow cytometry results and gRNA sequences.
Experiment Guide Sequence with PAM Chr
Cutting
position
Strand Type
Distance
from the
nearest exon
%Expression
deficient
(mean)
%Expression
deficient
(sd)
N
%Expression
deficient
(adj.mean)
PigA 5 GCAGTGAAGATAAATCACAAGGG 6 125472779 T NC - 0.4 0.3 6 -
PigA 15 CGTTGTGTCACAGTGCATAATGG X 164422321 NT intronic 260 12 3.3 6 -
PigA 62 TGTGACACAACGTTTAAAAGTGG X 164422349 T intronic 238 14 2.1 6 -
PigA 16 GAACATCTACTTGCTTAGCAGGG X 164422416 NT intronic 165 12 0.7 6 -
PigA 37 AAGGTTTCCAGAGCTACCCGGGG X 164422701 NT exonic - 60 2.0 6 -
PigA 56 GCAGAGAAAGAACTGTGGGAATGG X 164423023 NT exonic - 97 1.0 6 -
PigA 10 AGGAAGCCATAAGATAGCCACGG X 164423864 NT intronic 503 14 2.2 6 -
PigA 11 GCATAAGAGTGGATAAAACCAGG X 164423884 NT intronic 523 9.7 2.6 6 -
PigA 74 TGAGGTACTGTACCATGCACAGG X 164425741 NT intronic 2188 7.1 0.7 6 -
PigA 75 GAGGGTAAGTAACTCGCCCAAGG X 164425844 T intronic 2091 6.4 1.6 6 -
PigA 17 ACTTGTTCATACAGCCTACGTGG X 164427667 NT intronic 262 13 1.7 6 -
PigA 18 GATATGGGTATGTGGCAGTAGCGG X 164427749 T intronic 186 13 1.2 6 -
PigA 59 GGGACCAAAGAGAATCATTTTGG X 164428028 T exonic - 88 1.8 6 -
PigA 63 TGCCTCTTATAAATTGAAGCAGG X 164428148 NT intronic 86 8.9 1.8 6 -
PigA 12 ATAAGAGGCATGCAAATAGAAGG X 164428178 T intronic 110 13 1.6 6 -
PigA 13 CATACGAGCTGTGACACAACAGG X 164428347 T intronic 196 21 1.6 6 -
PigA 14 AAGTTGTGTCTATTACACTGGGG X 164428376 T intronic 167 16 2.2 6 -
PigA 48 ATGCAGAACGCTTCAGTGAGGG X 164428620 NT exonic - 96 1.3 6 -
Cd9 NC [untransfected or edited at PigA] - - - NC - 1.6 1.0 8 0
Cd9 81 GTGCAGAGCACGCCTTCACGGGG 6 125474376 NT intronic 1865 2.1 - 2 0.5
Cd9 84 GCAGTGTCCTTATCTAAGAGGGG 6 125474156 T intronic 1645 2.6 - 2 1.0
Cd9 82 ATGTAAGCCCCCTTAGTCCCCGG 6 125474028 T intronic 1517 2.7 - 2 1.1
Cd9 85 CAGCCAGCCACTACACTGGAGGG 6 125473582 T intronic 1071 2.0 - 2 0.4
Cd9 83 ACCTCTTATCACTGGTACCAGGG 6 125473547 NT intronic 1036 2.6 - 2 1.0
Cd9 5 GCAGTGAAGATAAATCACAAGGG 6 125472775 NT intronic 264 2.7 0.7 3 1.1
Cd9 86 CAACTGCAGCACTTCCGGCAGGG 6 125472720 T intronic 209 4.2 1.0 5 2.6
Cd9 6 GATTCACACACAGTTCCCTGCCGG 6 125472717 NT intronic 206 6.5 0.3 3 4.9
Cd9 78 CAGTGCTTGCTATTGGACTATGG 6 125472481 T exonic - 88 - 2 86
Cd9 35 TCTTGGTCTGAGAGTCGAATCGG 6 125472467 NT exonic - 88 2.2 7 87
Cd9 1 AAGGATGCCACCACTCCTGAGGG 6 125472162 T intronic 246 5.4 1.1 7 3.8
Cd9 2 ATTCAGGAAGCCGGTCTGGAGGG 6 125472028 NT intronic 380 3.5 - 2 1.9
Cd9 7 GGTTGTCCCCTAAGCATCAAGGG 6 125464747 T intronic 260 7.1 - 2 5.5
Cd9 8 TCAACACTCTACCTCATCCTCGG 6 125464703 NT intronic 216 3.6 0.2 3 2.0
Cd9 80 AGCCGGGGCCCTCATGATGCTGG 6 125464449 T exonic - 60 1.8 5 59
Cd9 79 GTACAGCTCCACAGCAGCCCAGG 6 125464432 NT exonic - 85 - 2 84
Cd9 3 GCCTGAAGTAAGGATGGTGAGAGG 6 125464252 NT intronic 137 4.6 - 2 3.0
Cd9 4 CTTTGTTTCCCCGATCTCGGTGG 6 125464003 T intronic 386 7.0 - 2 5.4
progenitor 311 GGGCGAGGAGCTGTTCACCGGGG - - T exonic - - - - -
cherry/gfp 33 GAAGTTCGAGGGCGACACCCTGG - - T exonic - - - - -
cherry/gfp 34 GGAACAGTACGAACGCGCCGAGG - - T exonic - - - - -
RPE1 231 AGGCTTCCCGCATTCAAAATCGG 3 46371987 NT NC - 0.2 0.0 3 -
RPE1 308 GTTGTAAGTACCAGAGTTGGTGG X 15324855 T exonic - 99 0.3 3 -
RPE1 307 TTTGGGAGCTTTAGAACACAAGG X 15325127 T exonic - 91 0.8 3 -
RPE1 278 GGATATTTCTGACAGAGTTCAGG X 15326014 NT exonic - 95 0.3 3 -
RPE1 277 GAATGTCTTAAGTGAGAGAGAGG X 15328488 T intronic 2278 2.7 0.7 3 -
RPE1 276 AGAGGGCAGGCCGTGTACGGTGG X 15330896 T intronic 323 8.1 2.1 3 -
RPE1 273 TGCTCAGGTACATATTTGTTCGG X 15331580 T exonic - 99 0.3 3 -
RPE1 272 GTAATAGACTTTGAGGCCACTGG X 15331674 NT exonic - 86 2.3 3 -
RPE1 274 TGGTAAACCATGATATGCTGTGG X 15332254 T intronic 261 9.4 0.6 3 -
RPE1 275 GGTAAAGTATAAGAGTAAAGGGG X 15332346 T intronic 353 3.2 1.6 3 -
Genomic position is given with respect to the GRCm38 or GRCh38 (RPE1 experiment) reference genome. Last
column contains negative control subtracted mean (Cd9 experiment). SD = standard deviation. Strand: T =
transcribed, NT = non-transcribed.
Chapter 5
Genotyping of complex lesions
5.1 Introduction
Most PCR-based genotyping of Cas9-induced le-
sions has so far focused on the region immedi-
ately adjacent to the cut site (<1000 bp) in bulk
cell populations. This biases the assessment by
excluding lesions that destroy the primer binding
sites (large deletions), disconnect them (translo-
cation and large inversions) or prevent amplifi-
cation by increasing the distance between them
(large insertions). Cas9-induced lesions that are
non-contiguous with the cut site and outside of
the amplified region are also missed. Failure to re-
cover such complex alleles is not apparent, when
genotyping in bulk cell populations. While some
specialized, PCR-based methods for detection of
such lesions in bulk populations exist, they are
not broadly used. PCR employed by these meth-
ods also has to be anchored in one flank of of
the break, which biases the output (Cain-Hom
et al., 2017; de Vree et al., 2014; Giannoukos
et al., 2018; Zheng et al., 2014).
Here, I addressed some of these issues by com-
bining long-range PCR with Sanger and PacBio
sequencing to detect and describe complex Cas9-
induced lesions in an unbiased way.
5.2 Results
5.2.1 Deletions underlying loss of gene ex-
pression caused by intronic gRNAs
In chapter 4, I showed that individual, intronic
gRNAs can cause loss of expression of the chro-
mosome X linked PigA in about 12% of trans-
fected male mouse ES cells. To understand what
genetic changes underlie this phenotype, I ampli-
fied a 5.7 kb region around exon 2 from pools
of cells mutagenized with three selected gRNAs
introduced by PiggyBac transposition and se-
quenced the PCR products using the PacBio plat-
form. I observed a depletion in read coverage on a
kilobase-scale around the cut sites, consistent with
the presence of large deletions (Fig. 5.2). Cells
mutagenized with intronic guides and sorted for
loss of PigA generally exhibited loss of the ad-
jacent exon 2 (Fig. 5.1a). If intronic regulatory
sequences were present around the exon, the DNA
of cells sorted for retention of PigA expression
would be wild type or contain only small indels
around the cut site. However, the most frequent
lesions in these cells were kilobase-scale deletions
extending away from the exon. I conclude that, in
most cases, loss of PigA expression was likely
caused by loss of the exon, rather than damage to
intronic regulatory elements.
PacBio sequencing of pooled edited DNA is
biased towards detection of large deletions. PCR
is more likely to amplify shorter amplicons, favor-
ing deletions. Capture of short fragments is also
more efficient during PacBio sequencing. Finally,
individual, shorter DNA molecules are usually
read more times during sequencing than longer
ones. As a consequence, they have higher quality
scores and are more likely to pass quality filters.
Another disadvantage of the PacBio approach is
the need to choose the amplicon size beforehand,
which means some alleles with larger lesions may
be missed. Finally, translocations cannot be am-
plified by a pair of fixed primers at all.
Therefore, to fully characterize the variety of
mutagenized alleles, I isolated single cell clones.
The loci around the gRNA target site were ampli-
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Figure 5.1: Positions of primer pairs and gRNAs used for genotyping experiments (Table 5.1 and 5.3). Genomic
position is given with respect to the GRCm38 or GRCh38 reference genome. In grey, primers used for diagnostic
PCRs on alleles that could not be recovered.
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Figure 5.2: Analysis of the PigA locus mutagenized with selected gRNAs. Coverage of PacBio reads at the
PigA locus. The locus was PCR-amplified from a pool of cells sorted for PigA expression (or from the unsorted
population), and the resulting products were sequenced using the PacBio platform. The right panel depicts a
100 bp region centered at the cut site. NC: negative-control gRNA, ex: exonic gRNA (#56), 5’ : 5’ intronic gRNA
(#15), 3’ : 3’ intronic gRNA (#10). The cut site of the gRNA is indicated with a vertical black bar. Genomic
position is given with respect to the GRCm38 reference genome. N = 1.
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(c) 3’ intronic guide #10, PiggyBac method.
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Figure 5.3: Alleles recovered by Sanger sequencing from Cas9-edited, PigA-deficient mouse ES cell clones.
The position of the gRNA is shown as a vertical line. Pure insertions and deletions of <50 bp are indicated with
orange and black circles, respectively. Combined insertion/deletion events of <50 bp and SNPs ("indel (<50 bp)"
in the legend) are indicated with a red circle. Black lines represent deletions >50 bp. Orange bars indicate size of
the >50 bp insertions (but not their map position). They are centered on the insertion locus or on the associated
deletion. Gray shades represent exons 2 (large one), 3, 4 and 5. X-axis represents distance from the gRNA position
in kilobases. Alleles are sorted by total length. Their names are indicated on the left.
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Figure 5.4: Alleles recovered by Sanger sequencing from PIGA-deficient, human female RPE1 cell clones.
Cas9-expressing cells were transiently transfected with gRNA-expressing plasmids. Grey shade represents exon 2.
Names of individual alleles are indicated in the column on the left. Dotted horizontal line separates clones. Other
display conventions as in Fig. 5.3.
fied using PCR primer pairs positioned progres-
sively further apart (up to 12-16 kb), until ampli-
cons were generated (see Fig. 5.1 for primers and
gRNAs positions). Long elongation times were
used to identify large insertions. Since mouse ES
cells were grown on feeder cells (which help main-
tain their pluripotency), primer pairs which specif-
ically exclude feeder cell DNA were used to avoid
spurious wild-type alleles at the PigA locus. This
could not be achieved at the Cd9 locus due to
low divergence between BL6 and feeder genomes.
Amplicons were Sanger (all loci) or PacBio (only
Cd9 locus) sequenced. Since no wild-type CAST
alleles were detected in any of the clones edited at
the Cd9 locus, I assumed all wild-type BL6 alleles
in these clones were feeder derived.
Consistent with the results from PacBio se-
quencing, large deletions of >50 bp were detected
in almost 85% (79/93) of PigA-deficient single
cell clones generated by single, intronic gRNAs
#10 and #15 (Fig. 5.3a and Fig. 5.3c). Most of
them overlapped both the cut site and the near-
est exon. The deletions varied in size, the largest
spanning 9.5 kb. Identical results were obtained
using electroporation of intronic gRNA #15 as
RNP (Fig. 5.3b), as expected due to consistent
rates of PigA-deficient cells between PiggyBac
and RNP methods (chapter 4).
To assess the frequency of large deletions
without strong selection for that outcome, I used
the exonic guide #56 causing 97% PigA loss. Al-
though two-thirds of alleles (32/48) from PigA-
deficient cells had indels <50 bp, as expected, 20%
(10/48) had deletions >50 bp, extending up to 6 kb.
Some of the deletions exhibited clear directional-
ity. Assuming this is also the case for deletions
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induced by intronic guides, this explains why the
observed rate of PigA loss with those guides is
only ~12% (chapter 4), not 20%. It is also consis-
tent with the depletion of read coverage distal to
the exon in PacBio analysis (Fig. 5.2).
To replicate these results in another mouse ES
cell line, I genotyped AB2.2 ES cell clones mutag-
enized at a hemizygous GFP or mCherry targeted
transgene using the PiggyBac method. The lower
frequency of deletions in these cells (7-12% vs
the expected 20%, Table 5.1, “cherry/gfp” exper-
iment)) is likely due to relatively shorter range
of the PCR (<3 kb vs 16 kb). Consistently, no
amplicon at all could be obtained in 15-26% of
clones.
In chapter 4, I have shown that intronic
gRNAs cause similar levels of PigA loss in both
mouse ES cells and in human female differenti-
ated RPE1 cell line. Consequently, I expected the
rate of deletions in these cells to also be similar.
I mutagenized RPE1 cells with intronic guides at
the PIGA gene, isolated PIGA-deficient single cell
clones and resolved their alleles using long-range
PCR (up to 12 kb) and Sanger sequencing. Only
deletions on the active chromosome X would be
selected for in these cells, so I expected the rate
of deletions on this chromosome to approximate
85% (as in PigA-deficient male ES cells mutage-
nized with intronic guides). Conversely, selection
should not affect the inactive chromosome, re-
sulting in the unselected rate of 20% (as in ES
cells mutagenized with the exonic guide). The ob-
served frequency of deletions in RPE1 cells is 47%
(40/85), very close to the expected 51% (85%*0.5
+ 20%*0.5; Fig. 5.4a, 5.4c and 5.4b). The largest
deletion spanned 6 kb. All but four deletions over-
lapped both the cut site and the nearest exon.
Frequent deletions were also observed in
mouse ES cells edited with intronic gRNA #1
at the bi-allelic Cd9 locus. The rate of deletions
was highest in the Cd9low (42/43) and lowest in
"true wild-type" clones (17/55). Intermediate lev-
els of deletions were observed in bimodal and
"low turned wild-type" clones expressing inter-
mediate levels of Cd9 (as defined in chapter 4,
Fig. 5.5). See subsection 5.2.5 for a more in-depth
discussion taking into account the allelic compo-
sition of individual clones.
To show that large deletions at the Cd9 locus
occur regardless of the choice of gRNA, I muta-
genized the biallelic Cd9 locus using two single
intronic guides (#1 and #86; two replicates) and
two single exonic guides (#35 and #80; one repli-
cate), sorted for cells expressing different Cd9 lev-
els, reassessed the expression of isolated clones
and genotyped the clones using long-range PCR
(Table 5.1, "cbbcs1" and "cbbcs3" experiments,
Fig. 5.1c). In all examined groups a substantial
fraction of clones had at least one deletion (18-
88%). In particular, cells mutagenized with in-
tronic guides and sorted for loss of gene expres-
sion collectively exhibit higher rates of deletion
clones (50-88%) than cells sorted for retention
of gene expression (33-46%). "Low turned wild-
type" and bimodal clones exhibited an interme-
diate frequency of deletions (43-71%). In clones
mutagenized with exonic gRNAs a large deletion
is not necessary to ablate gene expression, as a
small indel would have the same effect. Conse-
quently, there was not clear correlation between
clone expression level and fraction of deletion
clones (range: 17-42%).
5.2.2 Deletions in primary bone marrow
cells
Mouse ES cells can maintain pluripotency in cul-
ture for many passages. However, culture con-
ditions could temporarily influence the DDR in
these cells. Therefore, I replicated my results
in primary cells. I chose to work with progen-
itor cells from the bone marrow of mice ex-
pressing Cas9-GFP from a transgene at the ho-
mozygous Rosa26 locus. Lineage-negative cells
enriched by removal of differentiated cells on
magnetic columns were electroporated with a
crRNA:trRNA complex against the GFP locus.
GFP-negative single cell clones were isolated and
genotyped around the cut site with three different
primer pairs spanning in total 5 kb (Fig. 5.1d). At
least one large deletion product between 100 bp
and ~3 kb in size was detected in 36% of clones
(35/96; Table 5.1, “progenitor” experiment). I veri-
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fied eight deletion products by Sanger sequencing
across the deletion junction (Fig. 5.1e). Only wild-
type-size products were detected in the remaining
clones and none of the 96 control clones exhibited
any deletion bands (data not shown).
Observed frequency of deletions per clone
was identical to the expected rate (36%), given
20% probability of each allele sustaining a dele-
tion (as at the hemizygous PigA locus in mouse ES
cells mutagenized with the exonic guide). How-
ever, the range covered by genotyping PCR was
much smaller than in ES cells (5 kb vs 16 kb).
While this result confirms large deletions are com-
mon, it also suggests that the real frequency is
higher than expected, which may be a locus or
cell-specific difference.
I have attempted to test this hypothesis by
replicating the results at the Cd45 locus (Ptprc) in
an F1 cross combining two isoforms (Cd45.1 and
Cd45.2), whose expression can be distinguished
through specific antibody staining. Initial experi-
ments indicated that double knock-out is lethal in
progenitor cells, as this population appeared only
transiently in culture and did not form colonies
when isolated by FACS (data not shown). Target-
ing PigA in progenitor cells failed to result in ab-
lation of FLAER staining by day 11 post-delivery,
at which point the experiment was terminated. It is
possible that the effect would have been observed
later. I decided not to target the Cd9 locus, as with-
out near 100% electroporation efficiency loss of
Cd9 expression induced by intronic gRNAs would
be very low. Furthermore, re-assessment of Cd9
expression status in outgrown colonies would not
be possible using flow cytometry due to very low
cell numbers. An immunofluorescence procedure
could have been developed for that purpose.
5.2.3 Insertions
Insertions (incl. duplications and inversions), de-
fined as ≥10 bp fragments, which did not map in
a linear fashion to the mutagenized locus, were
present in 7-29% of resolved alleles from PigA,
PIGA and Cd9 loci. In almost all samples the most
common origin of insertions was the edited locus
(~62% of all insertions). This category ranged in
size from small duplications <20 bp templated
right next to the deletion breakpoint to perfect
inversions of 3.9 kb (Fig. 5.4c). Fragments of
E.coli genomic DNA and transfected plasmids
up to 5 kb were found at all three examined loci,
regardless of whether transfection was transient or
involved mobilization of the PiggyBac transposon
(Fig. 5.8). Distal insertions from introns and repet-
itive elements (predominantly LINE) were also
present in a few samples. Notably, identity of four
insertions of 13-29 bp could not be established,
suggesting one non-templated or a few stitched,
short, templated insertions.
One of the alleles derived from PacBio se-
quencing of the edited PigA locus contained an
insertion with a perfect match to four consecutive
exons derived from the Hmgn1 gene (Fig. 5.8a).
It could represent a de novo insertion from the
spliced and reverse-transcribed RNA, rather than
from one of the pseudogenized forms of Hmgn1,
as the pseudogenes diverge in sequence from the
functional gene and thus from the observed inser-
tion.
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(a) Cd9low clones.
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(b) Wild-type clones, that were sorted for low expres-
sion ("low turned wild-type").
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(d) Wild-type clones, that were sorted for wild-type
expression ("true wild-type").
Figure 5.5: Alleles recovered by Sanger and PacBio sequencing from CAST/BL6 mouse ES cell clones mutage-
nized at the Cd9 locus with the 3’ intronic gRNA #1. PiggyBac constructs were stably delivered by transposition
into Cas9-expressing cells. Gray shade represents exon 2. Dotted horizontal line separates clones. Clones are
sorted by the number of alleles. Color behind allele names indicates strain of origin. Other display conventions as
in Fig. 5.3.
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Table 5.1: Results of PCR genotyping.
Experiment gRNA Gene Primer pairs
Amplicon
size [bp]
Target
region
Sorted
population
Clone
expression
Total
clones
≥1 del. ≥1 ins. No amp. % del.
cbbcs1 1 Cd9 5F/5R, 1F/1R 1063, 5554 intron wt wt 24 9 2 0 38%
cbbcs1 1 Cd9 5F/5R, 1F/1R 1063, 5554 intron low wt 14 6 3 0 43%
cbbcs1 1 Cd9 5F/5R, 1F/1R 1063, 5554 intron low low 10 5 0 1 50%
cbbcs1 35 Cd9 5F/5R, 1F/1R 1063, 5554 exon wt wt 24 7 1 0 29%
cbbcs1 35 Cd9 5F/5R, 1F/1R 1063, 5554 exon medium wt 20 7 0 0 35%
cbbcs1 35 Cd9 5F/5R, 1F/1R 1063, 5554 exon medium loss 4 2 0 0 50%
cbbcs1 35 Cd9 5F/5R, 1F/1R 1063, 5554 exon loss loss 24 4 3 1 17%
cbbcs1 80 Cd9 6F/6R, 3F/3R 1266, 5865 exon medium medium 24 7 0 0 29%
cbbcs1 80 Cd9 6F/6R, 3F/3R 1266, 5865 exon loss loss 24 10 1 0 42%
cbbcs1 86 Cd9 5F/5R, 1F/1R 1063, 5554 intron wt wt 24 8 1 0 33%
cbbcs1 86 Cd9 5F/5R, 1F/1R 1063, 5554 intron low wt 2 1 0 0 50%
cbbcs1 86 Cd9 5F/5R, 1F/1R 1063, 5554 intron low low 22 17 1 0 77%
cbbcs3 1 Cd9 4F/4R, 1F/1R, 2F/2R 1263, 5554, 11968 intron wt wt 24 11 2 0 46%
cbbcs3 1 Cd9 4F/4R, 1F/1R, 2F/2R 1263, 5554, 11968 intron low bimod. 12 8 3 0 67%
cbbcs3 1 Cd9 4F/4R, 1F/1R, 2F/2R 1263, 5554, 11968 intron low wt 31 22 5 0 71%
cbbcs3 1 Cd9 4F/4R, 1F/1R, 2F/2R 1263, 5554, 11968 intron low low 29 25 1 2 86%
cbbcs3 86 Cd9 5F/5R, 1F/1R 1063, 5554 intron wt wt 24 10 1 0 42%
cbbcs3 86 Cd9 5F/5R, 1F/1R 1063, 5554 intron low bimod. 11 9 3 0 82%
cbbcs3 86 Cd9 5F/5R, 1F/1R 1063, 5554 intron low wt 29 16 4 0 55%
cbbcs3 86 Cd9 5F/5R, 1F/1R 1063, 5554 intron low low 32 28 3 0 88%
progenitor 311 GFP 1F/2R, 1F/1R, 2F/2R 1314, 2994, 3507 exon neg N/A 96 35 0 2 36%
cherry/gfp 33 GFP 1F/1R, 1F/3R 972, 2291 exon neg neg 89 11 4 13 12%
cherry/gfp 34 mCherry 2F/2R, 2F/3R 1258, 2968 exon neg neg 46 3 3 12 7%
cherry/gfp 34 mCherry 2F/2R, 2F/3R 1258, 2968 exon neg pos 2 0 0 0 0%
Cells were edited with indicated guides, sorted for different gene expression levels (“Sorted population”), single cell cloned and reassessed for gene expression
levels (“Clone expression”). bimod. - bimodal, ≥1 del. - one or more deletion amplicons observed, ≥1 del. - one or more insertion amplicons observed, No
amp. - no amplicons, % del. fraction of clones with deletions amplicons.
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5.2.4 Non-contiguous lesions
Notably, 13% of all alleles detected in single
cell clones (56/428) contained additional lesions
(SNPs, indels, large deletions and insertions) that
were non-contiguous with the lesion at the cut
site (Fig. 5.8b, c and d). This number is likely an
underestimate due to stringent filtering of such
variants at the Cd9 locus (see Methods) and due
to limited range of Sanger sequencing at the PigA
and PIGA loci. For about 30% of non-contiguous
lesions (17/56), the only exonic lesion detected
was non-contiguous with the cut site. Furthermore,
I observed alleles in which the intronic gRNA
caused an inversion of a region containing the
exon (Fig. 5.8c). Had the assessment been lim-
ited to the immediate vicinity of the cleavage site,
such alleles would have been misclassified as wild
type, and their phenotypic consequences would
have been wrongly called.
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Figure 5.6: Results of "diagnostic" PCRs and their
interpretations. Blue arrowheads indicate relative ori-
entation of genomic fragments.
5.2.5 Unexpected genotypes
of inconsistent clones
In mouse ES cells edited at the monoallelic PigA
locus and sorted for loss of gene expression, I ex-
pected every clone to yield exactly one allele with
a lesion overlapping the exon. One clone yielded
two alleles, likely a result of a picking two closely
growing colonies. Only seven out of remaining
164 clones did not contain a lesion overlapping
the nearest exon (three were wild-type around the
cut sites and four contained cut site, local lesions).
They likely contained lesions in other exons or
rearrangements outside of the amplified area that
could ablate gene expression (e.g. large inversions
containing the exon, insertions interfering with
splicing, translocations within the gene). Since ex-
pression status of these clones was not ascertained
after colony outgrowth, some of them could also
be PigA proficient.
In ten cases, it was not possible to recover
any product spanning the exon, even with a long-
range PCR (16 kb). To understand this class of
events, I performed additional, "diagnostic" PCRs
targeting each end of the PigA locus (Fig. 5.1a,
gray primers). In five cases, just one end or neither
end of the locus could be amplified, suggesting a
larger deletion. In the remaining five cases, both
ends were amplified. Since no product connecting
the two ends could be obtained, these are likely to
be translocations, large inversions or large inser-
tions (Fig. 5.3 and 5.6).
In female RPE1 cells edited at the PIGA locus
and sorted for loss of gene expression, I expected
every clone to yield exactly two alleles. At least
one of them, presumably on the active chromo-
some X, should contain a lesion overlapping the
nearest exon. No clone had more than two alleles
and all clones with exactly two alleles had at least
one exon-overlapping lesion, as expected. How-
ever, in about 32% of clones (14/44) only one
allele was detected with PCR up to 12 kb. This
could be due to a larger rearrangement (transloca-
tion, large deletion, insertion or inversion), which
would explain loss of PIGA expression. Alterna-
tively, five of the fourteen clones, in which an exon
overlapping lesion was detected, could be mono-
somic or homologous for these lesions (there was
no variants distinguishing the homologs). There-
fore, the frequency of undetected alleles can range
from 10% to 16% (9 or 14 alleles out of 88). The
lower bound of this range is consistent with the
rate of 8% (9/117) in mouse ES cell clones mu-
tagenized with intronic gRNAs at the PigA locus,
considering a slightly longer-range PCR was used
(16 kb vs 12 kb). Higher rate could indicate a
locus or cell-specific difference.
Clones derived from cells edited at the Cd9
locus could be broadly classified into Cd9low
5.2 Results 46
and Cd9-positive (ie. bimodal, "low turned wild-
type" and "true wild-type" clones; see chapter 4,
Fig. 4.4c). The haplosufficient nature of the Cd9
gene is demonstrated by the fact that I could de-
tect at least one intact exon 2 in each one of the
67 Cd9-positive clones. Conversely, almost all
Cd9low clones (25/26) had exon overlapping le-
sions in all detected alleles. The single exception
contained an intronic insertion with a polyA sig-
nal. Furthermore, gene dosage could largely ex-
plain the difference between "true wild-type" and
"low turned wild-type" clones. The first group
usually contained at least two functional exon 2s
(22/24), while the second group usually had ex-
actly one (27/30), consistent with their 50% lower
Cd9 expression (Fig. 5.5).
For experiments at the Cd9 locus, I used
mouse ES cells derived from an F1 cross between
BL6 and CAST mouse strains, which allowed me
to distinguish the homologous chromosomes. In
no case was the repair outcome identical between
homologs within a clone, despite 15 alleles re-
occurring between clones. Just over half of the
mutagenized clones (52/93) contained precisely
one BL6 and one CAST allele, as expected. No-
tably, in 18 clones only one allele was detected
with PCR spanning up to 12 kb, potentially due to
a larger rearrangement (translocation, large dele-
tion, insertions or inversions), monosomy or LOH.
Some of the wild-type BL6 alleles removed as
feeder-derived could be the missing alleles. An
abnormal number of alleles (two from the same
strain or more than two in total) was found in 21
clones, which could have resulted from picking
two closely growing colonies, large duplication,
repair events happening during clone outgrowth
or aneuploidy (spontaneous or induced by Cas9
cutting).
Two clones contained recombinant BL6-
CAST alleles (Fig. 5.9). In one case, a LOH event
distal to the breakpoints converted part of the
CAST allele to BL6. In another case, the BL6-
CAST crossover boundary did not coincide with
the breakpoint. I concluded that the creation of
these alleles likely involved interhomolog strand
invasion as they cannot be explained by a sim-
ple rejoining of the resected ends of two broken
chromosomes.
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Figure 5.7: Overlap between unique PigA alleles de-
rived using different methods. “PacBio” and “Single
cell” refer to alleles shown in Fig. 5.2, 5.3a, 5.3c and
5.3d. “Plasmid” alleles were derived in the same exper-
iment from subcloned PCR amplicons. “RNP” alleles
were derived in an independent experiment only using
guide #15 (Fig. 5.3b).
5.2.6 Diversity of resolved alleles at the PigA
locus
To gauge the diversity of mutagenesis outcomes,
I have compared unique, sequence resolved al-
leles that were derived in one experiment from
PigA-deficient mouse ES cells edited with intronic
gRNAs #10, #15 and an exonic gRNA #56 using
following three methods:
• PacBio sequencing of 5.5 kb PCR products
amplified from bulk DNA (2F/2R primer
pair in Fig. 5.1a; results in Fig. 5.2)
• Sanger sequencing of single cell clones,
with PCR product up to 16 kb in size (all
primer pairs in Fig. 5.1a; results in Fig. 5.3a,
5.3c, 5.3d)
• Sanger sequencing of individual 3.5 kb
PCR products amplified from bulk DNA
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Figure 5.8: Examples of alleles. The bottom diagram of each panel represents the PigA reference allele around
exon 2, the diagram immediately above shows the structure of the sequenced allele. Black horizontal line: di-
rect reference match; orange bar: inversion; blue bar: insertion from another part of the genome; violet bar –
duplication; black arrowhead: gRNA target site. Gray, orange and violet shadows represent, respectively, direct,
inverted and duplicated match between the reference and the sequenced allele. Lack of shadow at the reference
locus represents a deletion in the sequenced allele. (a) Putative insertion from a reverse transcribed RNA. The top
diagram line shows the genomic structure of Hmgn1; note the scale differs from that of PigA gene. (b) Exonic
lesion non-contiguous with the cut site. (c) Inversion of a region containing the exon. (d) "Scrambled" allele with
insertion from chromosome 16. (e) Combined deletion, local inversion and insertion from E.Coli genome. (f)
Duplication of a region containing the exon.
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Figure 5.9: Recombinant Cd9 alleles. Two of the sequenced single cell clones contained alleles indicative of a
cross-over event between the homologous chromosomes. Red vertical bars in CAST allele (gray bar) indicate
positions of sequence divergence from the BL6 reference genome (black bar), dotted black line indicates missing
sequence (deletion), thin black line indicates an intron. LOH: loss of heterozygosity.
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and cloned into plasmid vectors (1F/1R
primer pair in Fig. 5.1a)
Clustering of PacBio reads from PigA-
deficient samples yielded 168 unique alleles. The
majority of the alleles recovered from single cell
clones and plasmid cloned products were unique
(90/130 and 63/75, respectively; wild-type alle-
les excluded). In total 281 unique alleles were
recovered by the three methods, only 31 of which
(11%) were shared between two or three methods
(Fig. 5.7).
To make the comparison more reliable, I re-
moved alleles which could not be recovered with
the 3.5 kb primer pair (1F/1R) and small indels
(<10 bp), which were depleted from PacBio clus-
ters due to method-specific biases described in
subsection 5.2.1. Out of the remaining 145 unique
alleles only 18 (12%) were detected with more
than one method (Fig. 5.7).
I also compared the alleles in this experiment
with ones derived by single cell cloning of RNP
mutagenized cells, keeping only the alleles mu-
tagenized by the intronic gRNA #15. The only
overlap observed was between one out of the 21
unique RNP alleles and one allele in the plasmid
cloned group. I concluded that the large allelic
diversity of mutagenic outcomes may be difficult
to describe exhaustively using sequencing based
methods.
5.2.7 Diversity of deletion fingerprints at the
PigA locus
Diversity of deletion outcomes can be visualized
by resolving PCR products from pools of edited
cells on an agarose gel. If enough cells were used
in each experiment to avoid stochastic undersam-
pling of different deletion outcomes, the ladder-
like pattern corresponding to different deletion
sizes ("deletion fingerprint") should be similar be-
tween biologically independent replicates.
I repeated the original experiment four times
using intronic gRNA #15 in two mouse ES cell
lines, the original JM8 (also transfected with a
PiggyBac Cas9 vector) and its subclone express-
ing Cas9 from a single-copy lentiviral transgene.
I sorted PigA-deficient cells and performed 3.5 kb
PCR (1F/1R primer pair) on bulk extracted DNA.
I assumed 40% transfection and stable transpo-
sition efficiency of the gRNA plasmid, 15% fre-
quency of PigA loss due to intronic mutagenesis
(Fig. 4.2b), 20% plating efficiency of mouse ES
cells and ability to amplify 80% of PigA-deficient
alleles using the 3.5 kb PCR (35/43 among single
cell clones). Starting with 1.5 million cells this
translates into a transfection bottleneck of 15,000
individual cells with detectable deletions in the
Cas9 expressing line (Fig. 5.10a). After antibiotic
selection and population outgrowth, I sorted one
million cells from each sample, ensuring more
than 60x coverage of the bottleneck.
I asked whether sampling of 15,000 unique
cells bearing >200 bp deletions is enough to cover
the diversity of the possible deletion outcomes.
I assumed that the sorting step (with 60x cover-
age) did not reduce this initial diversity. However,
the PCR reaction itself could introduce stochas-
tic noise into the procedure, if too few products
were sampled from the pool of extracted genomic
DNA in each individual reaction. In order to en-
sure that PCR was not the limiting factor I have
performed a series of technical duplicate PCR re-
action starting with 250, 2,500 and 12,500 DNA
copies (80% of which should be possible to am-
plify with the “short” PCR) and compared their
"deletion fingerprints" (Fig. 5.10). Sampling 250
copies led to loss of technical reproducibility, as
PCR duplicates differed substantially. With 2,500
copies, the diversity of the biological replicate #4
was preserved, revealing it to be the least com-
plex in the set. Sampling 12,500 copies preserved
diversity of all replicates. Although some similari-
ties could be observed across biological replicates
and between the two cell lines in the same bio-
logical replicate, my general conclusion is that
sampling ~15,000 cells did not sufficiently cover
the diversity of deletion alleles.
5.3 Discussion
Using long-range PCR, I have genotyped in excess
of 850 single cell clones mutagenized with Cas9,
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Table 5.2: Summary classification of alleles.
Gene gRNA Target Expr. Method Indel
Deletion
>50 bp
Insertion
>10 bp
Multi
-Lesion
Intact
Exon
WT
Total
alleles
Total
clones
PigA 15 intron neg RNP 0 22 4 3 1 0 24 24
PigA 15 intron neg PiggyBac 0 40 9 10 1 1 48 48
PigA 10 intron neg PiggyBac 0 39 7 12 3 0 45 45
PigA 56 exon neg PiggyBac 32 10 6 1 2 2 48 47
PIGA 274 intron neg transient 7 19 4 2 12 3 32 16
PIGA 275 intron neg transient 12 16 6 5 15 0 34 19
PIGA 276 intron neg transient 6 5 4 0 8 2 22 9
Cd9 1 intron low PiggyBac 0 42 9 10 1 0 43 26
Cd9 1 intron bimod. PiggyBac 8 20 6 4 14 0 32 13
Cd9 1 intron l-wt PiggyBac 24 30 9 5 33 0 59 30
Cd9 1 intron wt PiggyBac 33 18 3 4 50 0 55 24
Expr.: expression class; bimod.: bimodal; l-wt: low turned wild-type; indel: small deletion and/or insertion only
(<50 bp); Intact exon: intact exon in the correct orientation. Categories are not mutually exclusive.
about 300 of which were also sequenced at the
mutagenized locus using Sanger and PacBio tech-
nologies. The results revealed a pervasive pres-
ence of large deletions (50 bp - 9.5 kb), which
explains frequent loss of gene expression upon
intronic cutting. Many complex rearrangements
of the locus, including large insertions, inver-
sion, translocation between homologs and non-
contiguous lesions were also discovered.
5.3.1 Consequences of large deletions
Large deletions could be pathogenic in gene ther-
apeutic context. Given that a target locus would
presumably be transcriptionally active, such mu-
tations could juxtapose it to the nearest onco-
gene, initiating neoplasia. A deletion inactivat-
ing a nearby tumor suppressor gene could predis-
pose the cell to become cancerous, even if only
one copy is affected (Santarosa and Ashworth,
2004). The effect might not be immediately obvi-
ous, as the lesions may constitute a carcinogenic
first "hit". This is especially true for stem cells and
progenitors, which have a long replicative lifespan
and may become neoplastic with time. This would
be similar to the activation of LMO2 by pro-viral
insertion in some of the early gene-therapy trials,
which caused cancer in these patient (Hacein-Bey-
Abina et al., 2003).
The closer the target site is to a cancer-driver
gene, the higher the risk posed by deletions and
other local rearrangements. I have not gathered
enough unbiased data at any locus to accurately
describe the frequency of "complex" lesions as a
function of distance from the cut site. However,
the gene expression data at the PigA locus comes
close. A simple exponential model can be fitted
using exon 2 proximal (100-500 bp) and distal
(~2 kb) gRNAs. I assumed that loss of PigA ex-
pression caused by gRNAs close to exon 2 is ex-
clusively due to damage to exon 2 (and not exon 1
or exon 3) and that the two gRNAs in the middle
of intron 2 confer double the risk by affecting both
exon 2 and 3 (data not shown). As a crude real-
ity check, I asked if the model correctly predicts
the tail of the distribution - the largest deletion in
the Sanger sequencing dataset (which is 9.5 kb
in total, 6.6 kb in one direction). Given 117 in-
tronically edited alleles from PigA-deficient cells
were tested, the model indicates on average 1.43
such lesions (or larger) should be found, which is
consistent with reality.
The lesion frequency under this model halves
with every kilobase of distance from the cut site.
This implies that for every 100 million mutage-
nized cells (the scale of current gene therapeutic
efforts), one lesion spanning 22.5 kb or more in
one direction from the cut site would be expected,
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on the average. While such calculations are sub-
ject to a very high statistical uncertainty and may
not generalize to other loci, they could inform
the design of future experiments with respect to
investigated distances and numbers of cells.
5.3.2 Consequences of other
complex lesions
Sequencing of single cell clones yielded large in-
sertions, inversions, non-contiguous lesions, cross-
overs and LOH events. Some of these were
directly implicated in causing gene expression
loss, notably inversions containing the exon, non-
contiguous lesions within the exons and an in-
tronic insertion containing polyA signal. Further-
more, the consequences of some of these lesions
would have been underestimated, if only geno-
typing around the cut site was performed. This
suggests that genotyping should not be limited to
the immediate vicinity of the cut site and stresses
the importance of careful phenotypic assessment,
whenever possible.
The full extent of non-contiguous lesions is
not known. Sanger sequencing was primarily per-
formed to detect deletion breakpoints, resolve in-
sertions and ensure integrity of the exon closest
to the cut site, so more distal lesions could have
been missed. I have observed some small, distal
indels in alleles derived by PacBio sequencing of
the Cd9 locus. However, I decided to filter them
out, as some of them consistently clustered at the
ends of the read (indicating quality issues) and in
low complexity regions (where accurate mapping
turned out to be an issue). Such lesions could be in-
vestigated in the future using more reliable Sanger
sequencing. As with large deletions, a quantitative
description of the frequency of non-contiguous le-
sions as a function of distance from the cut site
would be useful in gene therapeutic context.
Cas9-induced cross-overs would have mini-
mal impact if products co-segregate on cell di-
vision (i.e. undergo a "z-segregation"). If in-
stead they segregate away from each other
("x-segregation"), a cross-over would result in
chromosome-scale LOH, which could uncover
recessive alleles. If tumor suppressor genes are
affected, this could initiate cancer.
Analysis of single cell clones has indicated
presence of aneuploidies and alleles that could not
be fully resolved, such as translocations. These
events are often observed in cancers, due to their
ability to juxtapose active promoters and onco-
genes, amplify oncogenes and reduce the copy
number of tumor suppressors. I have not per-
formed a more detailed analysis of these clones,
but copy-number screening by qPCR or digital
droplet PCR, karyotyping to detect translocations
and SNP array genotyping for large scale dele-
tions and LOH events are warranted. Furthermore,
it would be crucial to establish the causal relation-
ship between Cas9 mutagenesis and aneuploidies,
as ES cells in culture are known to acquire aneu-
ploidies spontaneously.
Failure to detect one of the two lesions at an
autosomal locus in a single cell clone (or a founder
animal) can be easily mistaken for a homozygous
lesion. While in the context of animal mutagenesis
such mistake should be detected when animals fail
to breed true (as discussed in Shin et al., 2017), it
can significantly influence the interpretation of ex-
periments using single cell clones, whose alleles
cannot be easily isolated.
These considerations formed the basis of de-
bate, in which I was involved, on the interpreta-
tion of a particular human embryo editing study.
In that study, researchers used Cas9 to induce
a DSB on the paternal allele in human zygotes
and observed only the maternal allele in some
blastomers isolated from the multicellular embryo
three days later. In absence of further evidence, it
was concluded that the maternal allele served as
a template for the repair of the paternal allele, a
process termed "interhomolog repair" (Ma et al.,
2017). This conclusion has been challenged by
two groups as equally consistent with a failure
to detect the paternal allele due to destruction of
primer binding sites (Adikusuma et al., 2018; Egli
et al., 2018). One of these groups included data
which showed edited mouse embryos exhibit high
levels of large deletions. Reply to this criticism
reported no deletions with PCR spanning up to
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10 kb and established that at least some blastomers
carry the expected heterozygous patterns of SNPs
flanking the target site, which supports the original
conclusion (Ma et al., 2018). Another group inde-
pendently studying interhomolog repair in mouse
embryos also carried out the prescribed checks
(long-range PCRs, copy-number qPCR) and failed
to observe large losses of genetic material (Wilde
et al., 2018). With some other groups reporting
detection of large deletions in human embryos
and in differentiated animal tissues edited in vivo
(personal communication), it remains to be estab-
lished which conditions enable creation of com-
plex lesions (also see the Discussion chapter).
5.3.3 Stochasticity of large deletions
Indels induced by any gRNA are highly non-
random, with a few indels of particular sizes form-
ing a stable "indel profile". Such profiles are hy-
pothesized to be related to local microhomologies
guiding the repair process. I speculated an anal-
ogous "deletion profile" exists, potentially also
guided by homologies or larger scale secondary
structure of the DNA. Ladder pattern observed
by resolving amplicons from long-range PCRs
on pools of mutagenized cells initially seemed to
confirm this hypothesis. However, the observed
"profiles" differed between biological replicates.
Two possible explanations exists for the lack
of reproducibility of "deletion profiles". One is
that the potential diversity of induced deletions
far outstrips the number of transfected cells with
deletion outcomes. This would lead to stochastic
undersampling of deletion events in each trans-
fection replicate, resulting in a "noisy" profile.
If this model is correct, sampling more cells
should eventually reduce the noise between bi-
ological replicates. This could be achieved at a
scale by employing a non-leaky, inducible gRNA
and Cas9 system. Another explanation could be
clonal expansion due to stochastic genomic in-
stability. In this model, cells which acquired a
mutation that makes them grow faster (e.g. chro-
mosome 8 triploidy) selectively amplify the Cas9-
induced deletion they harbor. If this model is cor-
rect, a more karyotypically stable cell line should
behave more predictably. If such genomic instabil-
ity is independent of Cas9 mutagenesis, then even
wild-type cells will exhibit strong clonal effects,
which could be tested by random barcoding. Re-
gardless, my results revealed a source of noise that
needs to be taken into account when investigating
"deletion profiles".
5.3.4 Other considerations
Most of the "low turned wild-type" clones edited
at the Cd9 locus had exactly one exon-overlapping
and one non-overlapping lesion, as opposed to
"true wild-type" clones, most of which did not
have any exon-overlapping lesions. Although the
difference between these populations was not im-
mediately apparent in bulk cultures (Fig. 4.4a),
improved culturing protocols and use of single
cell clone controls could potentially allow sys-
tematic quantification and isolation of (or at least
enrichment for) cells with monoallelic "complex"
lesions at the Cd9 locus.
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(d) Deletion fingerprint - 12,500 copies per reaction.
Figure 5.10: PigA locus was mutagenized using 5’ intronic guide (#15) in biological quadruplicate. Duplicate
PCR reactions spanning the cut site performed on DNA extracted from the bulk of PigA-deficient cells and
resolved on an agarose gel (product size 3,500 bp, 1F/1R primer pair, Fig. 5.1a). JM8 – original mouse ES cell line
(transfected with gRNA and Cas9 PiggyBac vectors); CAS – JM8 subclone stably expressing Cas9 (transfected
only with a gRNA PiggyBac vector). Ladder scale is in kilobases.
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Table 5.3: Genomic primer pairs.
Gene Name Sequence Chr Start End Strand
PigA 1F CTTATGGGATGTACTGGGTCACTAG X 164421324 164421349 +
PigA 1R CACCCCAGAAAATGTAACTGAGTTC X 164424799 164424824 -
PigA 2F CTTTCATTTGGTTCATTATTTCTGTTCTTATC X 164420461 164420493 +
PigA 2R CCTTAACTCAAGAGCTGAACTT X 164425873 164425895 -
PigA 3F TTCGACCAGTTTGCTCTAACTCTTA X 164417878 164417903 +
PigA 3R ATCAAAGTGTCCTCGAGTTAAT X 164430740 164430762 -
PigA 4F AAGCTCTTAAGAGGAAAGGCTACAA X 164417360 164417385 +
PigA 4R ATCACACCACAGCATTAGGA X 164418508 164418528 -
PigA 5F TAACAGGTCACATATAGGATTTGGG X 164414904 164414929 +
PigA 6F ATGTGGAAATCCTGTACCAGAAAGA X 164429755 164429780 +
PigA 6R AACTGATTATCTGACCTTCCCT X 164423503 164423525 -
PigA 7F AGGAGACTGAGGCCAGGAATAT X 164421983 164422005 +
PIGA 1F CGGTTCACATGTTCCTGATTAAAGAA X 15328961 15328987 +
PIGA 1R GTGGTCGAGAATTTTACGGTAATGT X 15334958 15334983 -
PIGA 2F CTTTCCCGAACTTCTTCCAAAATGA X 15325931 15325956 +
PIGA 2R AGGCAGGACACCATAATTAGAATCA X 15337669 15337694 -
Cd9 1F CTTTAGTGTCCTTTTGCACACTTCT 6 125474857 125474882 -
Cd9 1R GGTATAACCAGTCCTTCTAGCACAT 6 125469328 125469353 +
Cd9 2F CTGTCGTGAAATATTAGGAAAGGGC 6 125477789 125477814 -
Cd9 2R AGTACCTCCCGTCTTGCTACC 6 125465846 125465867 +
Cd9 3F ATCTGAAGAAGTCTCTCTGACCCTA 6 125467206 125467231 -
Cd9 3R TCTTCTTTGGTGATTTGCTGATTCC 6 125461366 125461391 +
Cd9 4F AGTTTTCTGGTGATTTTACCGCAAT 6 125472672 125472697 -
Cd9 4R CCTTGTCAGAATGCTTTCTTGTCTT 6 125471434 125471459 +
Cd9 5F ATCATTTGGCATCCTATTCAACACC 6 125473010 125473035 -
Cd9 5R CTCCATCTCCATCCCCATTAATCTC 6 125471972 125471997 +
Cd9 6F AGGTCTCAGTAAGTTAGCTCAAGTG 6 125464803 125464828 -
Cd9 6R ATAAGGAGGTGTGATCAGTGGAAAA 6 125463562 125463587 +
Cas9-GFP 1F AGAAACTGAAGAGTGTGAAAGAGC - - - +
Cas9-GFP 1R CGTGCAATCCATCTTGTTCAATG - - - -
Cas9-GFP 2F GGCGGCAGGAAGATTTTTACCC - - - +
Cas9-GFP 2R GGGTGTTCTGCTGGTAGTGGT - - - -
cherry/gfp 1F GTAAACGGCCACAAGTTCAGC - - - +
cherry/gfp 1R GCTCAAGATGCCCCTGTTCT - - - -
cherry/gfp 2F GGAGGATAACATGGCCATCATCAAG - - - +
cherry/gfp 2R CTGATGCTCTTCGTCCAGATCA - - - -
cherry/gfp 3R TTGACCTATTCTGGCATTGTAGACA - - - -
Genomic position is given with respect to the GRCm38 or GRCh38.
Chapter 6
Discussion
6.1 Causes of complex lesions
Induction of DSB by Cas9 and subsequent repair
are clearly the necessary factors involved in cre-
ation of Cas9-induced complex lesions. However,
mechanistic details are unknown. Here, I specu-
late on three mutually non-exclusive factors con-
tributing to complex lesions and briefly review
tentative support for them in my data. I also dis-
cuss how these factors can be studied further.
First, generation of some complex lesions may
primarily involve double-strand resection. This
would explain deletions as a simple resection-and-
ligation reaction (presumably mediated in part
by components responsible for NHEJ). Further-
more, a double-stand resection could expose re-
peat sequences distal to the cut site. This in turn
could lead to SSA repair between exposed direct
repeats (resulting in more deletions) and to non-
allelic homologous recombination (NAHR) be-
tween repeats on different chromatids. NAHR is
the proposed mechanism for many large-scale re-
arrangements in cancer (deletions, duplications,
translocations and inversions).
Second, complex lesions could result from HR
repair being subverted by simultaneous breakage
of both sister chromatids at the same locus. Failing
to find an intact repair template, HR may either
mediate NAHR or the whole process may revert to
MMEJ. Normally, MMEJ involves limited single-
strand resection, but during an abortive attempt at
HR the DNA may be resected much more exten-
sively. This could expose distal homologies that
are not normally available to MMEJ. Synapsis of
these homologies could cause large deletions and
inversions.
Third, complex lesions could be stimulated
by Cas9-intrinsic properties, such as its exonucle-
ase activity and interference with DDR machinery
by staying bound to the DNA after making a cut.
This may influence the repair process, making rel-
atively non-mutagenic NHEJ and HR less likely,
both in favor of more mutagenic processes, such
as MMEJ or NAHR.
Data presented in this thesis does not clearly
exclude any of the three above mentioned mech-
anisms. Preliminary analysis has revealed that
the amount of exact homology at large deletion
breakpoints varies from zero to 12 nt (data not
shown), which indicates at least some deletions
may be a product of double-strand resection. A
more detailed comparison with the expected dis-
tribution of homology lengths will be necessary
to tell, whether MMEJ is likely to be involved.
Moreover, if recombination between repeats was
a major driver of large deletions, I would expect
them to emerge in "deletion fingerprinting" ex-
periments as reproducible, highly enriched dele-
tion bands. While these were not observed, it
may be either due to low sensitivity of the as-
say or due to low repeat content of the studied
PigA locus. Further analysis to explore inexact
homologies (i.e. stretches of homology with in-
frequent mismatches, also called "homeologies")
at deletion breakpoints could also help decide, if
repeat recombination is involved. Finally, many
small, locally templated insertions and small, non-
contiguous lesions implicate single-strand resec-
tion and MMEJ.
Dissection of requirements for complex le-
sions by means of genetic screens based on the
assay described in chapter 4 is warranted. Further-
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more, translocations could potentially be enriched
for and studied separately by targeting very long
introns and selecting for loss of gene expression
(although such selection will also enrich for very
large deletions and inversions). Systematic study
of different loci in the genome in this way would
allow better understanding of targets of transloca-
tions and thus proper risk estimation in the context
of gene therapy. A recent report found that distal
insertions induced by Cas9 (i.e. mapping to other
loci in the genome than the edited locus) are en-
riched for sequences close to the cut site in 3D
space (Leenay et al., 2018). I predict this would
also be the case for translocations. Finally, careful
comparison between different precision nucleases
may shed some light on whether Cas9-intrinsic
properties are contributing to creation of complex
lesions. However, such comparisons are often dif-
ficult due to many confounding factors, such as
differential levels of protein expression and nucle-
ase acitivity.
6.2 Ways to avoid complex lesions
Complex lesions are generally an undesirable out-
come of gene editing, both in gene therapy (where
they are potentially pathogenic, as discussed in
chapter 5) and in basic research (where they may
be confounding and difficult to genotype). Based
on the discussed causes of complex lesions, I
propose four broad ways of tackling this issue
- complete avoidance (or more controlled induc-
tion) of the DSB, avoidance of simultaneous chro-
matid breakage, manipulation of DDR and re-
engineering of the wild-type Cas9.
First, editing without DSB creation is possi-
ble in principle by using base editors. In practice,
indels consistent with DSB creation are observed
upon base editing at a rate of around 1% (Gaudelli
et al., 2017; Komor et al., 2016). Further engineer-
ing of base editing tools (e.g. using deactivated
instead of nickase Cas9, as in the first generation
of base editing Cas9) may help abolish DSBs com-
pletely or at least reduce them to marginal levels.
Another potential solution to the DSB problem is
creation of the break in a controlled fashion, as
for example during V(D)J recombination. These
reactions do still lead to carcinogenic transloca-
tions, but at a very low rate (Alt et al., 2013).
Discovery or engineering of a programmable re-
combinase could achieve this goal. Initial foray in
this area has been made by fusing Cas9 and Gin
recombinase, but this enzyme only operates on
specific recombinase recognition sites (Chaikind
et al., 2016). Finally, precise modification of the
DNA has been demonstrated in yeast transfected
with ssDNA complementary to the lagging strand
(Barbieri et al., 2017). This approach could po-
tentially be adapted to human cells. However, no
systematic safety assessment of this method has
been conducted yet.
Second, ensuring that only one sister chro-
matid is broken at any given time could be
achieved e.g. by reducing the effective concen-
tration of the nuclease, choosing low efficiency
guides or reducing the activity of the Cas9-gRNA
complex by engineering of its components. This
does not necessarily require having one Cas9
molecule per cell, but only that on the average the
activity should be low enough to induce one cut ev-
ery few hours, to allow HR to finish the repair pro-
cess. While initially the editing efficiency would
drop, it may be possible to maintain a level of nu-
clease activity that is low enough to avoid break-
ing both chromatids, but high enough to keep the
reaction going despite creation of new wild-type
alleles due to DNA replication. Alternatively, the
cutting could be confined to non-replicative stages
of the cell cycles, e.g. by coupling Cas9 to cell
stage specific degrons (Huang et al., 2017) or tim-
ing the delivery in synchronized cells (for analo-
gous approaches trying to increase HR repair see
Gutschner et al., 2016; Lin et al., 2014; Yang et al.,
2016a).
Third, blocking excessively mutagenic DSB
repair pathways or promoting ’safe’ ones could be
a promising way of avoiding complex lesions, pro-
viding these mechanisms are well understood. In
basic research, such modulation could be achieved
by overexpression and silencing of specific DDR
proteins. However, this could have unexpected
consequences at other loci than the edited one.
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Coupling Cas9 to proteins involved in DNA repair
or to the repair template (if templated repair is the
goal, e.g. Savic et al., 2018; Shou et al., 2018) is a
more "topical" solution, which may be compatible
with gene therapy.
Fourth, re-engineering of Cas9 to abolish ex-
onuclease activity or make it release DNA after
cut could potentially improve its risk profile. A
molecular evolution approach could perhaps be
employed, if selective conditions against exonu-
clease activity / extended binding and for high
endonucleotic activity can be obtained. However,
there is a risk that these properties are inextri-
cably linked. In particular, while a simple DSB
would predominantly be repaired with no change
to DNA sequence, a more complex, Cas9-blocked
DSB may elicit more vigorous, mutagenic repair
mechanisms.
6.3 Ways to exploit complex lesions
Cas9-induced cross-overs have already been used
in yeast to enable genetic mapping at higher res-
olutions than allowed by natural recombination
rate (Sadhu et al., 2016). "Distal" translocations,
which cause a more dramatic reshufling of the
genome, could be used to investigate the effect of
putting different loci in a linkage disequilibrium
and the significance of the particular chromoso-
mal setup of a given organism. Other forms of
genome engineering are already being used in this
field, for example in a recent work in which all of
yeast chromosomes were combined into one (or
two) units (Luo et al., 2018a; Shao et al., 2018).
Single gRNA-induced deletions could be a
useful tool for studying non-coding elements (en-
hancers, long non-coding RNAs etc.). In contrast
to coding genes, which can be inactivated by in-
troduction of a small, frameshifting indel, non-
coding elements usually require more extensive
mutagenesis. Such approach could complement
currently available tools, which use CRISPRi,
saturation mutagenesis or paired gRNA-induced
deletions (Aparicio-Prat et al., 2015; Canver et al.,
2015; Gasperini et al., 2017, 2018; Korkmaz et al.,
2016; Zhu et al., 2016). Due to its simplicity,
it could potentially match the throughput of the
CRISPRi approach, if multiple gRNAs are mul-
tiplex per cell (despite the confounding risk of
translocations between multiple cut sites). This
would make it possible to study the effect of tens
of thousands deletions in one experiment. Such
deletions could also be isolated and studied in
detail, as opposed to less well defined chromatin
silencing induced by CRISPRi.
Single gRNA-induced deletions of varying
size could be exploited to create genomic "dele-
tion series". Normally, exonic deletions are cre-
ated through Cre recombination between lox sites
flanking the exon. This approach offers a high
degree of precision. However, that also means
potential confounding factor may not be discov-
ered, if e.g. a regulatory element is consistently
co-deleted with the exon. An exonic deletion se-
ries could easily be created by single gRNA in
exons of moderate size (100-5000 bp). By intro-
ducing slight variability in resulting genotypes,
this approach could make the experiment more ro-
bust. Another application of this technique could
be to investigate the extent and the function of
different protein domains. Normally, this is done
by cloning of the cDNA of interest ("DNA com-
plementary to the mRNA", containing only the
coding part of the gene without introns) into a
plasmid and deleting various elements in vitro.
The modified product is then usually transiently
expressed from the plasmid in the cells knocked-
out for the endogenous gene. Using single gRNAs,
a deletion series could be created either directly
in the wild-type gene (if studying large exons) or
at a locus in which the endogenous gene was re-
placed with its cDNA copy. The advantage of this
approach over the current solution is that it could
be done at a larger scale and in the endogenous
regulatory context.
6.4 Probing protein isoform diversity us-
ing CRISPR/Cas9-based assays
I have detected a variety of discrete protein ex-
pression levels following Cas9 mutagenesis at the
Cd9 locus. Although I have not investigated them
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in detail, it is likely they represent stable isoforms
brought about by specific types of genomic dam-
age (loss of exon, out-of-frame mutation, epitope
modifying mutation). Systematic mutagenesis of
the coding gene coupled to a continuous protein-
related readout (e.g. abundance of protein mea-
sured by a flow cytometry, functional assay or
depletion of specifically edited cells in case of an
essential genes) could therefore be used as a tool
to study the plasticity of protein isoforms. Abun-
dance, and ideally the specific sequence, of mRNA
could be measured in the same assay to provide
additional layer of information and decouple tran-
scriptional effects. In particular, such an assay
would enable investigation of general splicing and
folding rules, stability requirements, relationship
between conservation and essentiality of specific
protein domains as well as epitope malleability.
A similar procedure investigating functionality of
so-called variants of unknown significance in the
essential Brca1 gene has recently been described
(Findlay et al., 2018; Starita et al., 2018).
6.5 New methods for genotyping
of complex lesions
Reliable, unbiased, high throughput methods for
genotyping of complex lesions are necessary to
understand them in more detail, to monitor gene
therapy applications and to guide the development
of preventative measures.
Methods I used in this study suffer from a
number of shortcomings. Single cell cloning and
Sanger sequencing are low throughput. Flow cy-
tometric assay can only be applied to a subset
of transcriptionally active loci. PacBio sequenc-
ing of bulk DNA results in biased readouts. New
methods need to be developed to enable more
in-depth study and systematic monitoring of com-
plex lesions at other loci, in other cell types or
using other nucleases. Barcoding of PCR prod-
ucts in early cycles could improve PacBio readout
by removing amplification and sequencing biases
as well as allowing accurate genotyping of small
indels. Oligos preventing amplification of wild-
type and small indel products could be used to
enrich for complex lesions without the need for
selection based on a loss of gene expression. De-
pletion of wild-type products could also be per-
formed post-amplification, e.g. by hybridization
with complementary RNA and digestion using
duplex-specific nuclease (Zhulidov et al., 2004)
or using wild-type sequence-specific oligos conju-
gated to magnetic beads. Copy number profiling
using qPCR would allow quick assessment of the
extent of large deletions. RNA quantification by
qPCR and full-length RNA isoform sequencing
could also be used to approximately quantify the
frequency of complex lesions (incl. translocations
and small non-contiguous lesions) in genes whose
activity cannot be assessed by flow cytometry.
6.6 Complex lesions and risk manage-
ment
Direct consequences of complex lesions were dis-
cussed in chapter 5. Here, I discuss feasibility of
Cas9 usage in basic research and gene therapy
given these consequences.
As mentioned earlier, complex lesions can be
considered a nuisance in most basic research appli-
cations. The presence of a large deletion, insertion,
inversion or translocation can often be readily de-
tected as failure to amplify any mutant genotype
in the offspring of edited animals crossed to the
wild-type. However, it does incurr a cost in time
and money spent breeding and genotyping unsuit-
able lesions. Complex lesions can compromise
interpretation of multiplexed editing, if animals
are not sufficiently backcrossed to the wild-type,
as lack of mutant detection in F1 animals cannot
be interpreted as lack of editing. Non-contiguous
lesion in F1 animals may also go unnoticed, unless
a proper rescue experiment is performed. These
problems compound when using single cell cloned
cell lines, whose alleles cannot be separated by
breeding. In practical terms, complex lesions high-
light the necessity for well established experimen-
tal controls - careful assessment of expression
and functional phenotypes, use of independently
derived cell clones or edited animals and rescue
experiments.
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In terms of gene therapy, two factors seem
crucial - whether editing is somatic or germline
and whether the purpose of the gene editing exper-
iment is curative or prophylactic. Whether the
therapy is conducted ex vivo or in vivo is an-
other important factor, since the former allows
a higher degree of quality control and may reduce
the risk of affecting long-lived proliferative stem
cells. Currently, the discovery of complex lesions,
our general understanding of off-target effects and
dearth of studies on long-term consequences of
gene editing in relevant animal models (such as
monkeys) or in humans suggests extreme caution
when considering gene therapeutic application be-
yond life-saving interventions. Therapies for ter-
minal diseases (incl. most forms of cancer), where
risk of cancer induced by Cas9 is outweighed by
the imminent risk of death, fall squarely into the
life-saving category. Consistently, therapies for
cancer using ex vivo edited T cells are currently
a major focus of gene therapeutic clinical trials.
There is also a "grey zone" of applications that
may not be life-saving, but are life-changing. One
example may be the potential cure for patients
with Hunter’s or Hurler’s syndrome, in which case
a physician may elect together with the patient to
accept the risk of carcinogenesis in exchange for
a potential cure. Finally, prophylactic attempts
aimed at reducing cholesterol levels (Pcsk9 edit-
ing, not yet in clinical trials) or prevent (but not
cure) HIV infection (Ccr5 editing) and most forms
of therapeutic embryo editing, which is bound to
influence the germline (especially, when preim-
plantation diagnostics offers a viable alternative),
may need to be deferred until our understanding
of Cas9 mutagenesis improves. Finally, I want to
acknowledge that the ultimate decision as to if
and when to allow usage of Cas9 and other preci-
sion nucleases on patients should be primarily in
the hands of people with extensive experience in
healthcare related risk management - physicians
running clinical trials and regulators specializing
in drug safety.
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